Original Article
Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
N Engl J Med 2009; 360:1395-1407April 2, 2009DOI: 10.1056/NEJMoa0810177
- Abstract
Background
Statins reduce the incidence of cardiovascular events in patients at high cardiovascular risk. However, a benefit of statins in such patients who are undergoing hemodialysis has not been proved.
Methods
We conducted an international, multicenter, randomized, double-blind, prospective trial involving 2776 patients, 50 to 80 years of age, who were undergoing maintenance hemodialysis. We randomly assigned patients to receive rosuvastatin, 10 mg daily, or placebo. The combined primary end point was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Secondary end points included death from all causes and individual cardiac and vascular events.
Results
After 3 months, the mean reduction in low-density lipoprotein (LDL) cholesterol levels was 43% in patients receiving rosuvastatin, from a mean baseline level of 100 mg per deciliter (2.6 mmol per liter). During a median follow-up period of 3.8 years, 396 patients in the rosuvastatin group and 408 patients in the placebo group reached the primary end point (9.2 and 9.5 events per 100 patient-years, respectively; hazard ratio for the combined end point in the rosuvastatin group vs. the placebo group, 0.96; 95% confidence interval [CI], 0.84 to 1.11; P=0.59). Rosuvastatin had no effect on individual components of the primary end point. There was also no significant effect on all-cause mortality (13.5 vs. 14.0 events per 100 patient-years; hazard ratio, 0.96; 95% CI, 0.86 to 1.07; P=0.51).
Conclusions
In patients undergoing hemodialysis, the initiation of treatment with rosuvastatin lowered the LDL cholesterol level but had no significant effect on the composite primary end point of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. (ClinicalTrials.gov number, NCT00240331.)
Media in This Article
Figure 1
Changes in Levels of Lipids and C-Reactive Protein, According to Study Group.Figure 2
Kaplan–Meier Curves for the Primary End Point in the Two Study Groups.Article Activity
- Article
Patients undergoing maintenance hemodialysis have a greatly increased risk of premature cardiovascular disease.1,2 However, the pattern of cardiovascular disease in such patients differs from that in the general population, and although the risk of myocardial infarction is increased, other cardiovascular events, such as sudden cardiac death and heart failure, predominate. 1-3 Moreover, the relationship between cardiovascular disease and conventional risk factors is inconsistent, inverse, or U-shaped.1,2,4 Since low-density lipoprotein (LDL) cholesterol levels may be low or normal in patients with advanced renal disease, there is particular uncertainty regarding the use of lipid-lowering therapy.1,2,4,5
Statin therapy has been proved to reduce the incidence of cardiovascular events and mortality in diverse patient populations at increased risk.3,6-10 Observational studies have suggested that statin therapy is also associated with improved survival among patients undergoing hemodialysis,11 and statin use is endorsed by clinical guidelines in many countries,12,13 but a benefit of statin therapy in these patients has not been proved. The only large-scale trial involving this population, Die Deutsche Diabetes Dialyse Studie (the 4D study),14 showed no significant benefit of statin therapy with regard to a composite cardiovascular end point in patients with type 2 diabetes who were undergoing hemodialysis. Some have attributed the lack of benefit to the very high cardiovascular risk among patients with type 2 diabetes and end-stage renal disease and to the futility of a single intervention.1,2,15 However, the question of the efficacy of statin therapy for the greater population of recipients of hemodialysis remains unanswered. A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events (AURORA) was therefore designed to investigate the effects of statin therapy in patients undergoing regular hemodialysis treatment.
Methods
Study Design
AURORA was a randomized, double-blind, placebo-controlled, multicenter trial.16,17 The study was conducted in accordance with the ethical principles of the Declaration of Helsinki, the Good Clinical Practice guidelines of the International Conference of Harmonisation, and local regulatory requirements; it was approved by ethics committees at all participating centers.
The executive steering committee designed the trial and supervised its conduct in collaboration with the sponsor, AstraZeneca. The sponsor collected the trial data and analyzed them according to a predefined statistical analysis plan. The analyses were verified by Dr. A.H. Zwinderman, an independent statistician at the Department of Clinical Epidemiology, Biostatistics, and Bioinformatics, University of Amsterdam. The manuscript was prepared and submitted for publication by the steering committee; the academic authors had access to the study data and vouch for the accuracy and completeness of the reported analyses.
Patients
Men and women 50 to 80 years of age who had end-stage renal disease and had been treated with regular hemodialysis or hemofiltration for at least 3 months were recruited from 280 centers in 25 countries. The major exclusion criteria were statin therapy within the previous 6 months, expected kidney transplantation within 1 year, and serious hematologic, neoplastic, gastrointestinal, infectious, or metabolic disease (excluding diabetes) that was predicted to limit life expectancy to less than 1 year. Other exclusion criteria were a history of a malignant condition, active liver disease (indicated by an alanine aminotransferase level that was more than three times the upper limit of the normal range), uncontrolled hypothyroidism, and an unexplained elevation in the creatine kinase level to more than three times the upper limit of the normal range.16,17
Eligible patients were randomly assigned (in blocks of four in a 1:1 ratio) to receive either rosuvastatin, 10 mg daily, or matching placebo. Follow-up visits were scheduled to occur 3 months after randomization and then every 6 months. Assessments included laboratory evaluations once yearly and, at each visit, pill counts and structured interviews to assess potential adverse events. Blood samples were analyzed at a central laboratory for levels of lipids and high-sensitivity C-reactive protein. A closeout visit occurred after termination of the study.
End Points
The primary end point was the time to a major cardiovascular event, defined as a nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes. All myocardial infarctions, strokes, and deaths were reviewed and adjudicated by a clinical end-point committee whose members were unaware of the randomized treatment assignments, in order to ensure consistency of the event diagnosis.
Secondary end points included all-cause mortality, cardiovascular event–free survival (i.e., freedom from nonfatal myocardial infarction, nonfatal stroke, death from cardiovascular causes, and death from any other cause), procedures performed for stenosis or thrombosis of the vascular access for long-term hemodialysis (arteriovenous fistulas and grafts only), and coronary or peripheral revascularization, death from cardiovascular causes, and death from noncardiovascular causes.
Statistical Analysis
The initial calculation of statistical power was based on an estimated rate of major cardiovascular events in the placebo group of 11% per year. It was estimated that 620 events would be required for the analysis, assuming a 25% benefit of intervention, 90% power, and a two-sided significance level of 0.05. The trial was predicted to last 3.9 years.16
In 2005, after the publication of the results of 4D and related trials,3,14 we reevaluated the underlying assumptions of our trial. In the revised calculation of power, we assumed a neutral (0%) treatment effect on stroke14 and predicted a 19.5% reduction in the rate of major cardiovascular events with active therapy. With a two-sided significance level of 0.05 and 87% power, we estimated that 805 major cardiovascular events were required for analysis. An interim analysis was performed when 305 patients had reached a primary end point; continuation of the study was recommended by the data and safety monitoring board. The overall significance level was appropriately adjusted for the interim analysis.
In the primary intention-to-treat analyses, which included all patients who underwent randomization, an unadjusted Cox proportional-hazards model was used to compare the study groups and calculate hazard ratios (SAS software, version 8.2). The score test was used to calculate P values. Cox analyses of the primary outcome were performed in prespecified groups; subgroups were defined according to median values or values divided into thirds or according to condition (e.g., diabetes). P values for the interaction between the subgroup and treatment are reported. A Cox model adjusted for baseline covariates was estimated to investigate the association with outcomes.
For lipid data, analysis of variance with baseline values as covariates was used to test the difference (i.e., the percent change from baseline) between rosuvastatin and placebo. For the level of high-sensitivity C-reactive protein, a two-sample sign test was used. Values of more than 40 mg per liter (the upper limit of the assay for the laboratory) were set at 40 mg per liter.
Results
Patients
During the recruitment period, from January 2003 through December 2004, a total of 3021 patients were screened, and 2776 patients were randomly assigned to double-blind treatment with rosuvastatin at a dose of 10 mg (1391 patients) or placebo (1385 patients) (see the flow diagram in the Supplementary Appendix, available with the full text of this article at NEJM.org). A total of 245 patients did not undergo randomization: 19 had an adverse event, 156 did not fulfill screening criteria, and 70 chose not to participate. Of those enrolled, 3 patients were randomly assigned incorrectly and were not included in the intention-to-treat population, leaving a total of 2773 patients. The two groups of patients were well matched with respect to baseline characteristics (age, sex, and race or ethnic group) and concomitant therapy, as well as mean duration of dialysis therapy at baseline (Table 1Table 1
Baseline Characteristics of the Patients.).The mean length of follow-up was 3.2 years (maximum, 5.6). No patients were lost to follow-up. During the follow-up period, 1296 patients died. Of the 1164 deaths that were adjudicated, 648 were deaths from cardiovascular causes. Altogether, 804 patients had a major cardiovascular event, and 674 patients (332 who were receiving rosuvastatin and 342 who were receiving placebo) died while receiving the study drug. In addition, 440 patients (207 who were receiving rosuvastatin and 233 who were receiving placebo) discontinued the study medication after an adverse event, including study end points, and 370 patients (197 who were receiving rosuvastatin and 173 who were receiving placebo) discontinued therapy because of renal transplantation. The mean duration of exposure to the study medication was 2.4 years (median, 2.2).
Lipid and C-Reactive Protein Levels
Baseline lipid levels are shown in Table 1. At 3 months, the LDL cholesterol level in the rosuvastatin group was 42.9% lower than the baseline level (mean [±SD] difference, 42±30 mg per deciliter [1.1±0.8 mmol per liter]), as compared with a 1.9% reduction in the placebo group (mean difference, 1.9±23 mg per deciliter [0.05±0.59 mmol per liter]; P<0.001 for the between-group comparison) (Figure 1AFigure 1
Changes in Levels of Lipids and C-Reactive Protein, According to Study Group.). At 3 months, rosuvastatin also reduced the total cholesterol level, by 26.6% (by 47±35 mg per deciliter [1.2±0.9 mmol per liter]), as compared with a 0.5% reduction (1±27 mg per deciliter [0.03±0.70 mmol per liter]) in the placebo group (P<0.001), and the triglyceride level was reduced by 16.2% (by 26±71 mg per deciliter [0.29±0.80 mmol per liter]), as compared with an increase of 0.9% (1.8±72 mg per deciliter [0.02±0.81 mmol per liter]) in the placebo group (P<0.001) (Figure 1B). There was a modest increase of 2.9% in the high-density lipoprotein cholesterol level (1.2±10 mg per deciliter [0.03±0.26 mmol per liter]), as compared with an increase of 0.8% (0.4±9.3 mg per deciliter [0.01±0.24 mmol per liter]) in the placebo group (P=0.045) (Figure 1C). Toward the end of the study, there was a trend toward a convergence of the lipid levels in the active-treatment and placebo groups, probably reflecting withdrawals from active therapy and “drop-in” therapy with statins in the placebo group. The median high-sensitivity C-reactive protein level was elevated at baseline (Table 1) and decreased by 11.5% in the rosuvastatin group at 3 months (by 0.65 mg per liter, vs. an increase of 0.21 mg per liter in the placebo group; P<0.001) (Figure 1D).Primary Outcomes
The primary end point occurred in 396 patients assigned to receive rosuvastatin (9.2 events per 100 patient-years) and in 408 patients assigned to receive placebo (9.5 events per 100 patient-years) (Figure 2Figure 2
Kaplan–Meier Curves for the Primary End Point in the Two Study Groups. and Table 2Table 2
End Points According to Study Group.). There was no significant effect of active treatment (hazard ratio for the primary end point in the rosuvastatin group vs. the placebo group, 0.96; 95% confidence interval [CI], 0.84 to 1.11; P=0.59). Among the components of the primary end point, we also observed no significant effect of rosuvastatin therapy as compared with placebo. The respective event rates were 7.2 and 7.3 per 100 patient-years for death from cardiovascular causes (P=0.97), 2.1 and 2.5 per 100 patient-years for nonfatal myocardial infarction (P=0.23), and 1.2 and 1.1 per 100 patient-years for nonfatal stroke (P=0.42) (Table 2). A per-protocol analysis of patients who continued to receive active study medication until they reached a study end point confirmed the lack of an effect of rosuvastatin on the primary composite end point.Secondary Outcomes and Subgroups
Death from any cause occurred in 636 patients (13.5 per 100 patient-years) in the rosuvastatin group and 660 (14.0 per 100 patient-years) in the placebo group. There was no significant effect of rosuvastatin on all-cause mortality (hazard ratio, 0.96; 95% CI, 0.86 to 1.07; P=0.51) or on death from noncardiovascular causes (hazard ratio, 0.92; 95% CI, 0.77 to 1.09; P=0.34). None of the prespecified secondary outcomes were influenced by active treatment (Table 2). The lack of an effect of rosuvastatin therapy on the primary end point was consistent in all prespecified subgroups (Figure 3Figure 3
Hazard Ratio for the Primary End Point in Predefined Subgroups.), including patients with diabetes, preexisting cardiovascular disease, hypertension, a high LDL cholesterol level, or an elevated high-sensitivity C-reactive protein level. Subgroup analyses according to the overall time on hemodialysis therapy or the overall time on renal-replacement therapy also did not influence the response to therapy (data not shown).Adherence to Study Therapy and Adverse Events
According to tablet counts, 91.7% of rosuvastatin tablets and 89.5% of placebo tablets were taken as intended by patients in the study. Consistent with previous studies in patients with end-stage renal disease, there was a high incidence of adverse and serious adverse events.3,14 Adverse events were reported in 1338 patients who received rosuvastatin (96.3%) and in 1332 patients who received placebo (96.7%). Serious adverse events were reported in 1140 patients who received rosuvastatin (82.1%) and in 1159 patients who received placebo (84.1%). Most patients reported multiple events; a total of 36,780 adverse events and 9017 serious adverse events were reported during the study, with no significant difference between treatment groups (Table 3Table 3
Monitored Adverse Events and Measured Laboratory Values in the Safety-Analysis Population.).Relationship between Lipid Levels and Outcomes
Given the lack of a treatment effect of rosuvastatin on the primary end point, we examined the relationship between lipid levels and cardiovascular end points within the trial. There was no relationship between the primary cardiovascular end point and either baseline LDL cholesterol levels (hazard ratio per 1 mg per deciliter [0.03 mmol per liter], 1.00; 95% CI, 0.82 to 1.29; P=0.83) or LDL cholesterol levels at 3 months (hazard ratio, 0.95; 95% CI, 0.83 to 1.09; P=0.48).
Discussion
In this trial, we examined the potential benefits of statin therapy with regard to the increased cardiovascular risk associated with maintenance hemodialysis therapy.1,2,4,16,17 We found no effect of rosuvastatin on the primary end point of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes. Analyses of individual components of the primary end point and of several secondary end points were consistent with the main finding. Rosuvastatin had no benefit in any subgroup examined, including patients with diabetes.16,17
The lack of a benefit of rosuvastatin was observed despite a mean 43% reduction in the LDL cholesterol level at 3 months and the expected benefits with regard to other lipid levels.3,6-10,14 As expected in a population of patients undergoing hemodialysis, baseline cholesterol levels were not high. However, in the subgroup analyses (Figure 3), there was no benefit at any baseline LDL cholesterol level or in groups with preexisting cardiovascular disease, regardless of the lipid level. Previous studies4 have shown an inconsistent (or inverse) relationship between the LDL cholesterol level and outcomes in patients undergoing hemodialysis.1,2,4 Our findings suggest that in such patients, a reduction of the LDL cholesterol level with statins does not necessarily reduce cardiovascular risk.
In the 4D study,14,18 1225 patients with type 2 diabetes undergoing maintenance hemodialysis received either atorvastatin at a dose of 20 mg or placebo. Although the median LDL cholesterol level was reduced by 42% with atorvastatin, there was no significant reduction in the composite primary cardiovascular end point. In contrast, previous trials and post hoc analyses have shown benefits of statin therapy in patients with diabetes, including diabetes with less advanced chronic kidney disease.19-22 The lack of a benefit of statin therapy in the 4D and AURORA studies suggests that cardiovascular disease in patients undergoing hemodialysis differs from that in other patients.23,24
Other trials examining cardiovascular outcomes in patients with chronic kidney disease have been limited to post hoc assessments of patients recruited for cardiovascular prevention trials,19-21 studies of modest size,22 and studies involving patients treated by means of renal transplantation.3,25 In these studies, statin therapy has been shown to reduce the incidence of cardiovascular events.6-10,26 These results contrast with the lack of benefit in patients undergoing hemodialysis seen in our trial and raise the questions of whether statin therapy becomes ineffective with worsening renal disease and, if so, at which stage? These questions may be answered by the ongoing Study of Heart and Renal Protection (SHARP) (ClinicalTrials.gov number, NCT00125593),27 which will evaluate the benefit of simvastatin plus ezetimibe in patients across the spectrum of renal dysfunction.
There are several caveats to consider with regard to interpretation of our results. First, we excluded patients who were already receiving statins. Although we do not have a registry that would enable us to examine this excluded group systematically, we estimate that it may account for as many as 35 to 40% of all patients with end-stage renal disease. This group may include patients who had previously had cardiac events or had undergone cardiovascular interventions and may also include patients for whom statins were initiated at earlier stages of progressive kidney disease. We also observed a lower-than-predicted yearly event rate for the primary end point.1,2,16,28 Thus, we cannot rule out selection bias or the possibility that investigators excluded patients whom they believed warranted statin therapy.
Another issue is that we recruited patients who were 50 to 80 years of age, even though the increase in cardiovascular risk affects all age groups of patients undergoing hemodialysis therapy28 and is disproportionately higher among younger patients. Thus, possible benefits in younger patients, most of whom will ultimately receive transplants, were not explored in our trial. Finally, a high proportion of patients discontinued the study medication during the study; this is a reflection of the difficulties in performing clinical trials in this population, with high incidences of adverse events and hospitalization for coexisting illness, as well as the unpredictable availability of renal transplants. The main reasons for discontinuation of therapy were transplantation, adverse events, and study end points. It is possible that the withdrawal rate masks the potential benefit of statin therapy, although the high discontinuation rate is partly a consequence of the high event rate and is consistent with the findings of the 4D study.14,18
Increasingly, the benefits of statin therapy are attributed to pleiotropic effects that are independent of a lowering of the LDL cholesterol level, and they include improvements with respect to endothelial function and inflammation29 and a reduction of the high-sensitivity C-reactive protein level. In the recent Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) (NCT00239681),10 involving subjects without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels (≥2.0 mg per liter), rosuvastatin reduced both the high-sensitivity C-reactive protein level (by 37%) and major cardiovascular events (by 44%). In contrast, in our trial, although high-sensitivity C-reactive protein levels were elevated at baseline (by 5.0 mg per liter) and were decreased by rosuvastatin, there was no reduction in cardiovascular events. This finding may reflect different causes of elevated high-sensitivity C-reactive protein levels in patients undergoing hemodialysis.
AURORA and 4D are not the only studies to show a lack of benefit of statin therapy in specific populations. Patients in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) (NCT00206310)30 and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca Heart Failure Study (GISSI-HF) (NCT00336336)31 trial had heart failure and low ejection fractions. Like the patient population in our study, patients in these two trials had advanced disease associated with coexisting conditions and had significant reductions in lipid and high-sensitivity C-reactive protein levels with statin treatment, but no reduction in cardiovascular end points.
Safety concerns have limited the use of statin therapy in patients with renal disease.1,2 We observed no increase in the incidence of muscle-related adverse events, rhabdomyolysis, or liver disease in the rosuvastatin group as compared with the placebo group. Five cases of rhabdomyolysis were reported during the trial (in two patients receiving placebo and in three patients receiving rosuvastatin). Concern has also been expressed about an excess risk of cancer related to statin therapy,32,33 but no increase in the number of new cancer diagnoses was seen in our trial. In the 4D study,14,18 atorvastatin was associated with an increased incidence of stroke, although the numbers were small. We found no significant effect of rosuvastatin on the incidence of stroke, but there was a marginal increase in hemorrhagic strokes in patients with diabetes who received rosuvastatin (12 events, vs. 2 events in patients with diabetes in the placebo group; P=0.03), which is consistent with the findings of the 4D study.14,18 Although concern was expressed about an increase in physician-reported cases of diabetes with rosuvastatin in the JUPITER trial,10 we did not find an excess of new-onset diabetes.
In conclusion, the AURORA trial evaluated the effect of rosuvastatin on cardiovascular events in a population of patients with end-stage renal disease. Despite significantly reducing the levels of LDL cholesterol and high-sensitivity C-reactive protein, treatment with rosuvastatin was not associated with a reduction in the combined end point of myocardial infarction, stroke, or death from cardiovascular causes.
Dr. Fellström reports receiving consulting fees from AstraZeneca, Novartis, Roche, and Wyeth, lecture fees from Astellas, Novartis, and Roche, and grant support from Novartis, Roche, Merck–Schering-Plough, and Wyeth and serving as national coordinator for the Study of Heart and Renal Protection (SHARP) study at Oxford University's Clinical Trial Service Unit; Dr. Jardine, receiving consulting fees from Novartis, AstraZeneca, and Wyeth and lecture fees from Novartis and Astellas; Dr. Schmieder, receiving consulting and lecture fees from AstraZeneca, Novartis, Merck Sharp & Dohme, and Pfizer; Dr. Holdaas, receiving consulting fees from Novartis, AstraZeneca, and Schering-Plough and lecture fees from Novartis and AstraZeneca, and serving as national coordinator for the SHARP study; Dr. Bannister, receiving consulting fees from Baxter, Amgen, and Genzyme, lecture fees from Servier and Boehringer Ingelheim, and grant support from Amgen; Dr. Beutler, receiving lecture fees from Pfizer; Dr. Chevaile, receiving consulting fees from AstraZeneca; Dr. Cobbe, receiving consulting fees and grant support from AstraZeneca; Dr. Grönhagen-Riska, receiving grant support from AstraZeneca and serving as national coordinator for the SHARP study; Dr. De Lima, receiving consulting fees from AstraZeneca; Dr. Lins, receiving consulting fees from AstraZeneca and Novartis and lecture fees from Servier and Sanofi-Aventis; Dr. Mayer, receiving consulting fees from AstraZeneca and Genzyme, lecture fees from Genzyme and Amgen, and grant support from Amgen; Dr. McMahon, receiving consulting fees from AstraZeneca and Schering-Plough and lecture fees from AstraZeneca; Dr. Parving, receiving consulting and lecture fees from AstraZeneca, Merck, and Novartis and having equity ownership and stock options in Novo Nordisk; Dr. Remuzzi, serving on the Prospective Evaluation of Proteinuria and Renal Function in Diabetic Patients with Progressive Renal Disease (PLANET) and AURORA advisory committees for AstraZeneca; Dr. Samuelsson, receiving lecture fees from AstraZeneca; Dr. Sonkodi, receiving lecture fees from AstraZeneca, Richter Gedeon Nyrt, and Egis Nyrt; Dr. Tesar, receiving lecture fees from Amgen and Novartis; Dr. Wiecek, receiving consulting fees from AstraZeneca; Dr. Wüthrich, receiving consulting fees from Amgen, Genzyme, Novartis, and Vifor, lecture fees from Amgen, Vifor, and Wyeth, and grant support from Amgen, Genzyme, Novartis, Vifor, and Wyeth; Mr. Gottlow, being an employee of and owning stock or having other ownership interest in AstraZeneca; Dr. Johnsson, being an employee of and owning stock or having other ownership interest in AstraZeneca; and Dr. Zannad, receiving consulting fees from Servier, Novartis, ResMed, Daiichi Sankyo, Pfizer, AstraZeneca, and Merck and lecture fees from Pfizer, Daiichi Sankyo, Servier, and Medtronic. All authors except for employees of AstraZeneca received honoraria for serving on the steering committee of the AURORA study. No other potential conflict of interest relevant to this article was reported.
This article (10.1056/NEJMoa0810177) was published on March 30, 2009, and was updated on April 14, 2010, at NEJM.org.
We thank all the participating patients, study nurses, investigators, and members of the AURORA data and safety monitoring board and clinical end-point committee for making the trial possible; Dr. A.H. Zwinderman (Amsterdam) for independent data analysis; and Karin Sabel (AstraZeneca, Mölndal, Sweden), study team leader. AstraZeneca provided and funded editorial support for an earlier version of the article.
Source Information
The affiliations of the authors are listed in the Appendix.
Address reprint requests to Dr. Fellström at the Department of Medical Science, Renal Unit, University Hospital, SE-751 85, Uppsala, Sweden, or at bengt.fellstrom@medsci.uu.se.
Members of A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events (AURORA) Study Group are listed in the Supplementary Appendix, available with the full text of this article at NEJM.org.
Appendix
The authors' affiliations are as follows: University Hospital, Uppsala (B.C.F.), Sahlgrenska University Hospital, Gothenburg (O.S.), and AstraZeneca, Mölndal (M.G., E.J.) — all in Sweden; British Heart Foundation Glasgow Cardiovascular Research Centre, Glasgow, United Kingdom (A.G.J., S.M.C.); University Hospital, Erlangen-Nürnberg, Erlangen, Germany (R.E.S.); Rikshospitalet, Oslo (H.H.); Royal Adelaide Hospital, Adelaide, Australia (K.B.); Jeroen Bosch Hospital, 's-Hertogenbosch, the Netherlands (J.B.); Seoul National University Bundang Hospital, Kyounggi-do, South Korea (D.-W.C.); Hospital Central Dr. Ignacio Morones Prieto, San Luis Potosí, Mexico (A.C.); Helsinki University Hospital, Helsinki (C.G.-R.); Heart Institute (InCor) do Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo (J.J.D.L.); ZNA Stuivenberg, Antwerp, Belgium (R.L.); Medical University Innsbruck, Innsbruck, Austria (G.M.); University of Alberta Hospital, Edmonton, Canada (A.W.M.); Rigshospitalet, Copenhagen, and Aarhus University, Aarhus, Denmark (H.-H.P.); Azienda Ospedaliera, Ospedali Riuniti di Bergamo, Bergamo, Italy (G.R.); Szeged Scientific University, Szeged, Hungary (S.S.); Akdeniz University, Antalya, Turkey (G.S.); General Hospital of Veria, Veria, Greece (D.T.); Charles University, Prague, Czech Republic (V. Tesar); University Hospital, Pleven, Bulgaria (V. Todorov); Medical University of Silesia, Katowice, Poland (A.W.); University Hospital Zurich, Zurich, Switzerland (R.P.W.); and Centre d'Investigation Clinique, Centre Hospitalier Universitaire, and Nancy Université, Nancy, France (F.Z.).
- References
References
1
Sarnak MJ . Cardiovascular complications in chronic kidney disease. Am J Kidney Dis 2003;41:11-17
CrossRef | Web of Science | Medline2
Baigent C ,Burbury K ,Wheeler D . Premature cardiovascular disease in chronic renal failure. Lancet 2000;356:147-152
CrossRef | Web of Science | Medline3
Holdaas H ,Fellstrom B ,Jardine AG , et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003;361:2024-2031
CrossRef | Web of Science | Medline4
Liu Y ,Coresh J ,Eustace JA , et al. Association between cholesterol level and mortality in dialysis patients. JAMA 2004;291:451-459
CrossRef | Web of Science | Medline5
Vaziri ND . Dyslipidaemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 2006;290:F262-F272
CrossRef | Web of Science | Medline6
Baigent C ,Keech A ,Kearney PM , et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278[Erratum, Lancet 2005;366:1358, 2008;371:2084.]
CrossRef | Web of Science | Medline7
Thavendiranathan P ,Bagai A ,Brookhart MA ,Choudhry NK . Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med 2006;166:2307-2313
CrossRef | Web of Science | Medline8
Sever PS ,Dahlof B ,Poulter NR , et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361:1149-1158
CrossRef | Web of Science | Medline9
Ford I ,Murray H ,Packard CJ , et al. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007;357:1477-1486
Free Full Text | Web of Science | Medline10
Ridker PM ,Danielson E ,Fonseca FAH , et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195-2207
Free Full Text | Web of Science | Medline11
Mason NA ,Baillie GR ,Satayathum S , et al. HMG-CoA reductase inhibitor use is associated with mortality reduction in hemodialysis patients. Am J Kidney Dis 2005;45:119-126
CrossRef | Web of Science | Medline12
Kidney Disease Outcomes Quality Initiative (K/DOQI) Group 13
Chronic kidney disease in adults: UK guidelines for identification, management and referral. London: Royal College of Physicians, 2006. (Accessed March 12, 2009, at http://www.renal.org/CKDguide/full/UKCKDfull.pdf.)
14
Wanner C ,Krane V ,Marz W , et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005;353:238-248[Erratum, N Engl J Med 2005;353:1640.]
Free Full Text | Web of Science | Medline15
Baigent C ,Landray MJ ,Wheeler DC . Misleading associations between cholesterol and vascular outcomes in dialysis patients: the need for randomized trials. Semin Dial 2007;20:498-503
CrossRef | Web of Science | Medline16
Fellstrom B ,Zannad F ,Schmieder R , et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients -- design and rationale of the AURORA study. Curr Control Trials Cardiovasc Med 2005;6:9-9
CrossRef | Medline17
Fellstrom B ,Holdaas H ,Jardine AG , et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study. Kidney Blood Press Res 2007;30:314-322
CrossRef | Web of Science | Medline18
Krane V ,Winkler K ,Drechsler C , et al. Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes on hemodialysis. Kidney Int 2008;74:1461-1467
CrossRef | Web of Science | Medline19
Anavekar NS ,McMurray JJ ,Velazquez EJ , et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004;351:1285-1295
Free Full Text | Web of Science | Medline20
Tonelli M ,Jose P ,Curhan G ,Sacks F ,Braunwald E ,Pfeffer M . Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ 2006;332:1426-1426
CrossRef | Web of Science | Medline21
Tonelli M ,Isles C ,Curhan GC , et al. Effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 2004;110:1557-1563
CrossRef | Web of Science | Medline22
Geluk CA ,Asselbergs FW ,Hillege HL , et al. Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial. Eur Heart J 2005;26:1314-1320
CrossRef | Web of Science | Medline23
Herzog CA ,Mangrum JM ,Passman R . Sudden cardiac death and dialysis patients. Semin Dial 2008;21:300-307
CrossRef | Web of Science | Medline24
Guerin AP ,Pannier B ,Marchais SJ ,London GM . Arterial structure and function in end-stage renal disease. Curr Hypertens Rep 2008;10:107-111
CrossRef | Web of Science | Medline25
Holdaas H ,Fellstrom B ,Cole E , et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant 2005;5:2929-2936
CrossRef | Web of Science | Medline26
Shepherd J ,Kastelein JJ ,Bittner V , et al. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol 2008;51:1448-1454
CrossRef | Web of Science | Medline27
Baigent C ,Landry M . Study of Heart and Renal Protection (SHARP). Kidney Int Suppl 2003;84:S207-S210
CrossRef | Medline28
Foley RN ,Murray AM ,Li S , et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005;16:489-495
CrossRef | Web of Science | Medline29
Forrester JS ,Libby P . The inflammation hypothesis and its potential relevance to statin therapy. Am J Cardiol 2007;99:732-738
CrossRef | Web of Science | Medline30
Kjekshus J ,Apetrei E ,Barrios V , et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-2261
Free Full Text | Web of Science | Medline31
GISSI-HF Investigators,
Tavazzi L ,Maggioni AP , et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1231-1239
CrossRef | Web of Science | Medline32
Dale KM ,Coleman CI ,Henyan NN ,Kluger J ,White CM . Statins and cancer risk: a meta-analysis. JAMA 2006;295:74-80
CrossRef | Web of Science | Medline33
Shepherd J ,Blauw GJ ,Murphy MB , et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-1630
CrossRef | Web of Science | Medline
- Citing Articles (576)
Citing Articles
1
Patrick S. Parfrey, Brendan J. Barrett. Cardiovascular Disease and Chronic Kidney Disease. In: Chronic Renal Disease. Elsevier, 2015:181-198.
CrossRef2
Anne M. Murray, Stephen Seliger, John C. Stendahl. Neurologic Complications of Chronic Kidney Disease. In: Chronic Renal Disease. Elsevier, 2015:249-265.
CrossRef3
Dominic S. Raj, Roberto Pecoits-Filho, Paul L. Kimmel. Inflammation in Chronic Kidney Disease. In: Chronic Renal Disease. Elsevier, 2015:199-212.
CrossRef4
Christoph Wanner. Dyslipidemia and Chronic Kidney Disease. In: Chronic Renal Disease. Elsevier, 2015:706-710.
CrossRef5
Ashte’ K. Collins, Mark E. Rosenberg, Paul L. Kimmel. Clinical Assessment and Management of Chronic Kidney Disease Across its Stages. In: Chronic Renal Disease. Elsevier, 2015:43-54.
CrossRef6
Mark Shipeng Yu, David A. Folt, Christopher A. Drummond, Steven T. Haller, Emily L. Cooper, Pamela Brewster, Kaleigh L. Evans, Christopher J. Cooper. (2014) Endovascular Versus Medical Therapy for Atherosclerotic Renovascular Disease. Current Atherosclerosis Reports 16:12,
CrossRef7
David Charytan. (2014) Is left ventricular hypertrophy a modifiable risk factor in end-stage renal disease. Current Opinion in Nephrology and Hypertension 23:6, 578-585
CrossRef8
Suetonia C Palmer, Giovanni FM Strippoli, Jonathan C Craig. (2014) KHA-CARI commentary on the KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Nephrology 19:11, 663-666
CrossRef9
Alberto Martínez-Castelao, José L. Górriz, Jordi Bover, Julián Segura-de la Morena, Jesús Cebollada, Javier Escalada, Enric Esmatjes, Lorenzo Fácila, Javier Gamarra, Silvia Gràcia, Julio Hernández-Moreno, José L. Llisterri-Caro, Pilar Mazón, Rosario Montañés, Francisco Morales-Olivas, Manuel Muñoz-Torres, Pedro de Pablos-Velasco, Ana de Santiago, Marta Sánchez-Celaya, Carmen Suárez, Salvador Tranche. (2014) Documento de consenso para la detección y manejo de la enfermedad renal crónica. Endocrinología y Nutrición 61:9, e25-e43
CrossRef10
Theodoros I. Kassimatis, David J.A. Goldsmith. (2014) Statins in chronic kidney disease and kidney transplantation. Pharmacological Research 88, 62-73
CrossRef11
Alberto Martínez-Castelao, José L. Górriz, Jordi Bover, Julián Segura-de la Morena, Jesús Cebollada, Javier Escalada, Enric Esmatjes, Lorenzo Fácila, Javier Gamarra, Silvia Gràcia, Julio Hernández-Moreno, José L. Llisterri-Caro, Pilar Mazón, Rosario Montañés, Francisco Morales-Olivas, Manuel Muñoz-Torres, Pedro de Pablos-Velasco, Ana de Santiago, Marta Sánchez-Celaya, Carmen Suárez, Salvador Tranche. (2014) Documento de consenso para la detección y manejo de la enfermedad renal crónica. SEMERGEN - Medicina de Familia
CrossRef12
Alberto Martínez-Castelao, José L. Górriz, Jordi Bover, Julián Segura-de la Morena, Jesús Cebollada, Javier Escalada, Enric Esmatjes, Lorenzo Fácila, Javier Gamarra, Silvia Gràcia, Julio Hernández-Moreno, José L. Llisterri-Caro, Pilar Mazón, Rosario Montañés, Francisco Morales-Olivas, Manuel Muñoz-Torres, Pedro de Pablos-Velasco, Ana de Santiago, Marta Sánchez-Celaya, Carmen Suárez, Salvador Tranche. (2014) Documento de consenso para la detección y manejo de la enfermedad renal crónica. Hipertensión y Riesgo Vascular
CrossRef13
Alberto Martínez-Castelao, José L. Górriz, Jordi Bover, Julián Segura-de la Morena, Jesús Cebollada, Javier Escalada, Enric Esmatjes, Lorenzo Fácila, Javier Gamarra, Silvia Gràcia, Julio Hernández-Moreno, José L. Llisterri-Caro, Pilar Mazón, Rosario Montañés, Francisco Morales-Olivas, Manuel Muñoz-Torres, Pedro de Pablos-Velasco, Ana de Santiago, Marta Sánchez-Celaya, Carmen Suárez, Salvador Tranche. (2014) Documento de consenso para la detección y manejo de la enfermedad renal crónica. Atención Primaria
CrossRef14
G. M. Lucas, M. J. Ross, P. G. Stock, M. G. Shlipak, C. M. Wyatt, S. K. Gupta, M. G. Atta, K. K. Wools-Kaloustian, P. A. Pham, L. A. Bruggeman, J. L. Lennox, P. E. Ray, R. C. Kalayjian. (2014) Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected With HIV: 2014 Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clinical Infectious Diseases
CrossRef15
Penelope Ward, Mark Bodmer. Antibodies in Phase III Studies for Immunological Disorders. In: Handbook of Therapeutic Antibodies. Wiley-VCH Verlag GmbH & Co. KGaA, 2014:851-926.
CrossRef16
Stein Ivar Hallan. (2014) Cardiovascular Disease Prevention in CKD. American Journal of Kidney Diseases 64:3, 326-328
CrossRef17
Junichi Tazaki, Takeshi Morimoto, Ryuzo Sakata, Hitoshi Okabayashi, Fumio Yamazaki, Noboru Nishiwaki, Kazuaki Mitsudo, Takeshi Kimura. (2014) Impact of statin therapy on patients with coronary heart disease and aortic aneurysm or dissection. Journal of Vascular Surgery 60:3, 604-612.e2
CrossRef18
K. Jameson, S. Jick, K. W. Hagberg, B. Ambegaonkar, A. Giles, D. O'Donoghue. (2014) Prevalence and management of chronic kidney disease in primary care patients in the UK. International Journal of Clinical Practice 68:9, 1110-1121
CrossRef19
Alberico L. Catapano, Michel Farnier, JoAnne M. Foody, Peter P. Toth, Joanne E. Tomassini, Philippe Brudi, Andrew M. Tershakovec. (2014) Combination therapy in Dyslipidemia: Where are we now?. Atherosclerosis
CrossRef20
Gianluigi Savarese, Giuseppe M.C. Rosano, Antonio Parente, Carmen D’Amore, Martin F. Reiner, Giovanni G. Camici, Bruno Trimarco, Pasquale Perrone-Filardi. (2014) Reduction of C-reactive protein is not associated with reduced cardiovascular risk and mortality in patients treated with statins. A meta-analysis of 22 randomized trials. International Journal of Cardiology
CrossRef21
Yong Jin Yi, Hyo Jin Kim, Sang Kyung Jo, Sung Gyun Kim, Young Rim Song, Wookyung Chung, Kum Hyun Han, Chang Hwa Lee, Young-Hwan Hwang, Kook-Hwan Oh. (2014) Comparison of the Efficacy and Safety Profile of Morning Administration of Controlled-release Simvastatin Versus Evening Administration of Immediate-release Simvastatin in Chronic Kidney Disease Patients With Dyslipidemia. Clinical Therapeutics 36:8, 1182-1190
CrossRef22
Francisco Lopez-Jimenez, Vinaya Simha, Randal J. Thomas, Thomas G. Allison, Ananda Basu, Regis Fernandes, R. Todd Hurst, Stephen L. Kopecky, Iftikhar J. Kullo, Sharon L. Mulvagh, Warren G. Thompson, Jorge F. Trejo-Gutierrez, R. Scott Wright. (2014) A Summary and Critical Assessment of the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Disease Risk in Adults: Filling the Gaps. Mayo Clinic Proceedings
CrossRef23
Peter P. Toth, George Thanassoulis, Ken Williams, Curt D. Furberg, Allan Sniderman. (2014) The Risk-Benefit Paradigm versus the Causal Exposure Paradigm: LDL as a Primary Cause of Vascular Disease. Journal of Clinical Lipidology
CrossRef24
S. C. Palmer, J. C. Craig, A. Jones, G. Higgins, N. Willis, G. F. M. Strippoli. (2014) Celebrating 20 years of evidence from the Cochrane Collaboration: what has been the impact of systematic reviews on nephrology?. Nephrology Dialysis Transplantation
CrossRef25
Michael S. Kostapanos, Christos V. Rizos, Moses S. Elisaf. (2014) Benefit–Risk Assessment of Rosuvastatin in the Treatment of Atherosclerosis and Related Diseases. Drug Safety 37:7, 481-500
CrossRef26
Itsuki Nagata, Amane Ike, Hiroaki Nishikawa, Bo Zhang, Makoto Sugihara, Ken Mori, Atsushi Iwata, Akira Kawamura, Kazuyuki Shirai, Yoshinari Uehara, Masahiro Ogawa, Shin-ichiro Miura, Keijiro Saku. (2014) Associations between lipid profiles and MACE in hemodialysis patients with percutaneous coronary intervention: From the FU-Registry. Journal of Cardiology
CrossRef27
William Herrington, Richard Haynes, Natalie Staplin, Jonathan Emberson, Colin Baigent, Martin Landray. (2014) Evidence for the Prevention and Treatment of Stroke in Dialysis Patients. Seminars in Dialysisn/a-n/a
CrossRef28
Pamela B. Morris, Christie M. Ballantyne, Kim K. Birtcher, Steven P. Dunn, Elaine M. Urbina. (2014) Review of Clinical Practice Guidelines for the Management of LDL-Related Risk. Journal of the American College of Cardiology 64:2, 196-206
CrossRef29
David M. Charytan. (2014) How is the Heart Best Protected in Chronic Dialysis Patients?. Seminars in Dialysis 27:4, 325-328
CrossRef30
Patrick B. Mark, Alison H. M. Taylor, Emily P. McQuarrie, Alan G. Jardine. (2014) How is the Heart Best Protected in Chronic Dialysis Patients?. Seminars in Dialysis 27:4, 328-332
CrossRef31
Martijn Dane, Bernard van den Berg, Ton Rabelink. (2014) The endothelial glycocalyx: Scratching the surface for cardiovascular disease in kidney failure. Atherosclerosis 235:1, 56-57
CrossRef32
Neil J. Stone, Jennifer G. Robinson, Alice H. Lichtenstein, C. Noel Bairey Merz, Conrad B. Blum, Robert H. Eckel, Anne C. Goldberg, David Gordon, Daniel Levy, Donald M. Lloyd-Jones, Patrick McBride, J. Sanford Schwartz, Susan T. Shero, Sidney C. Smith, Karol Watson, Peter W.F. Wilson. (2014) 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. Journal of the American College of Cardiology 63:25, 2889-2934
CrossRef33
S. V. Badve, S. C. Palmer, D. W. Johnson, G. F. M. Strippoli. (2014) A nephrology guide to reading and using systematic reviews of randomized trials. Nephrology Dialysis Transplantation
CrossRef34
M. Pauriah, D. H. J. Elder, S. Ogston, A. Y. S. Noman, A. Majeed, J. C. Wyatt, A.-M. Choy, T. M. MacDonald, A. D. Struthers, C. C. Lang. (2014) High-potency statin and ezetimibe use and mortality in survivors of an acute myocardial infarction: a population-based study. Heart 100:11, 867-872
CrossRef35
Cynthia Herrick, Marina Litvin, Anne Carol Goldberg. (2014) Lipid lowering in liver and chronic kidney disease. Best Practice & Research Clinical Endocrinology & Metabolism 28:3, 339-352
CrossRef36
A. Olyaei. (2014) Statins do not improve cardiovascular outcomes for dialysis patients. Evidence-Based Medicine 19:3, 89-89
CrossRef37
Christoph Wanner, Marcello Tonelli, Alan Cass, Amit X Garg, Hallvard Holdaas, Alan G Jardine, Lixin Jiang, Florian Kronenberg, Rulan S Parekh, Tetsuo Shoji, Robert J Walker. (2014) KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney International 85:6, 1303-1309
CrossRef38
Lin Wang, Wenjie Tian, Zaid Uwais, Guangyong Li, Huixi Li, Ruili Guan, Zhezhu Gao, Zhongcheng Xin. (2014) AGE-Breaker ALT-711 Plus Insulin Could Restore Erectile Function in Streptozocin-Induced Type 1 Diabetic Rats. The Journal of Sexual Medicine 11:6, 1452-1462
CrossRef39
Jagannath H. Saikumar, Csaba P. Kovesdy. (2014) What is the Role of Lipid Measurements in End-Stage Renal Disease?. Seminars in Dialysisn/a-n/a
CrossRef40
Iolanda Decorato, Anne-Virginie Salsac, Cecile Legallais, Mona Alimohammadi, Vanessa Diaz-Zuccarini, Zaher Kharboutly. (2014) Influence of an Arterial Stenosis on the Hemodynamics Within an Arteriovenous Fistula (AVF): Comparison Before and After Balloon-Angioplasty. Cardiovascular Engineering and Technology
CrossRef41
Meredith C. Foster, Andreea M. Rawlings, Elizabeth Marrett, David Neff, Morgan E. Grams, Bertram L. Kasiske, Kerry Willis, Lesley A. Inker, Josef Coresh, Elizabeth Selvin. (2014) Potential Effects of Reclassifying CKD as a Coronary Heart Disease Risk Equivalent in the US Population. American Journal of Kidney Diseases 63:5, 753-760
CrossRef42
Aidar R. Gosmanov, Barry M. Wall, Elvira O. Gosmanova. (2014) Diagnosis and Treatment of Diabetic Kidney Disease. The American Journal of the Medical Sciences 347:5, 406-413
CrossRef43
Ragnar Pálsson, Uptal D. Patel. (2014) Cardiovascular Complications of Diabetic Kidney Disease. Advances in Chronic Kidney Disease 21:3, 273-280
CrossRef44
Alberto Ortiz, Adrian Covic, Danilo Fliser, Denis Fouque, David Goldsmith, Mehmet Kanbay, Francesca Mallamaci, Ziad A Massy, Patrick Rossignol, Raymond Vanholder, Andrzej Wiecek, Carmine Zoccali, Gérard M London. (2014) Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. The Lancet 383:9931, 1831-1843
CrossRef45
Mark E Molitch, Amanda I Adler, Allan Flyvbjerg, Robert G Nelson, Wing-Yee So, Christoph Wanner, Bertram L Kasiske, David C Wheeler, Dick de Zeeuw, Carl E Mogensen. (2014) Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes. Kidney International
CrossRef46
Lewis W. Johnson, Ruth S. Weinstock. Medical complications of diabetes mellitus. In: Diabetes Mellitus and Oral Health. John Wiley & Sons, Inc, 2014:45-68.
CrossRef47
Bertram Kasiske, Takao Saito. (2014) The kidney and lipids: preface. Clinical and Experimental Nephrology
CrossRef48
David A. Drew, Mark J. Sarnak. (2014) Ischemic and Hemorrhagic Stroke: High Incidence in Hemodialysis and Peritoneal Dialysis Patients. American Journal of Kidney Diseases 63:4, 547-548
CrossRef49
Mark K. Elliott, Jennifer A. McCaughan, Damian G. Fogarty. (2014) Do patients with chronic kidney disease get optimal cardiovascular risk reduction?. Current Opinion in Nephrology and Hypertension1
CrossRef50
Harsha V. Ganga, Hanna B. Slim, Paul D. Thompson. (2014) A systematic review of statin-induced muscle problems in clinical trials. American Heart Journal
CrossRef51
Philip J. Millar, John S. Floras. (2014) Statins and the autonomic nervous system. Clinical Science 126:6, 401-415
CrossRef52
Guenther Silbernagel, Iris Baumgartner, Christoph Wanner, Winfried März. (2014) Toward Individualized Cholesterol-Lowering Treatment in End-Stage Renal Disease. Journal of Renal Nutrition 24:2, 65-71
CrossRef53
M. Bonthuis, K. J. van Stralen, K. J. Jager, S. Baiko, T. Jahnukainen, G. F. Laube, L. Podracka, T. Seeman, K. Tyerman, T. Ulinski, J. W. Groothoff, F. Schaefer, E. Verrina. (2014) Dyslipidaemia in children on renal replacement therapy. Nephrology Dialysis Transplantation 29:3, 594-603
CrossRef54
Sari Imamura, Kumiko Hirata, Makoto Orii, Kunihiro Shimamura, Yasutsugu Shiono, Kohei Ishibashi, Takashi Tanimoto, Takashi Yamano, Yasushi Ino, Hironori Kitabata, Tomoyuki Yamaguchi, Takashi Kubo, Atsushi Tanaka, Toshio Imanishi, Takashi Akasaka. (2014) Relation of Albuminuria to Coronary Microvascular Function in Patients With Chronic Kidney Disease. The American Journal of Cardiology 113:5, 779-785
CrossRef55
H. Moradi, E. Streja, M. L. Kashyap, N. D. Vaziri, G. C. Fonarow, K. Kalantar-Zadeh. (2014) Elevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients. Nephrology Dialysis Transplantation
CrossRef56
F. Hammer, V. Krane, S. Stork, C. Roser, K. Hofmann, N. Pollak, B. Allolio, C. Wanner. (2014) Rationale and design of the Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease Study (MiREnDa). Nephrology Dialysis Transplantation 29:2, 400-405
CrossRef57
Jian-Min Wang, Jia-Jun Zhou, Qian Zheng, Hua Gan, Hang Wang. (2014) Dialysis Method Alters the Expression of MicroRNA-33a and Its Target Genes ABCA1, ABCG1 in THP-1 Macrophages. Therapeutic Apheresis and Dialysis 18:1, 44-50
CrossRef58
Bertram Pitt, Patrick Rossignol. (2014) Mineralocorticoid Receptor Antagonists in Patients With End-Stage Renal Disease on Chronic Hemodialysis. Journal of the American College of Cardiology 63:6, 537-538
CrossRef59
Tarun W. Dasari, David J. Cohen, Neal S. Kleiman, Michelle J. Keyes, Chen-Hsing Yen, Elias B. Hanna, Jorge F. Saucedo. (2014) Statin Therapy in Patients With Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention (from the Evaluation of Drug Eluting Stents and Ischemic Events Registry). The American Journal of Cardiology 113:4, 621-625
CrossRef60
Kunitoshi Iseki. (2014) Epidemiology of dyslipidemia in chronic kidney disease. Clinical and Experimental Nephrology
CrossRef61
Miao Hu, Brian Tomlinson. (2014) Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin. Expert Opinion on Drug Metabolism & Toxicology 10:1, 51-65
CrossRef62
Marcello Tonelli. (2014) The Roads Less Traveled? Diverging Research and Clinical Priorities for Dialysis Patients and Those With Less Severe CKD. American Journal of Kidney Diseases 63:1, 124
CrossRef63
Oliver T Browne, Victoria Allgar, Sunil Bhandari. (2014) Analysis of factors predicting mortality of new patients commencing renal replacement therapy 10 years of follow-up. BMC Nephrology 15:1, 20
CrossRef64
Georges Khoueiry, Mokhtar Abdallah, Faisal Saiful, Nidal Abi Rafeh, Muhammad Raza, Tariq Bhat, Suzanne El-Sayegh, Kamyar Kalantar-Zadeh, James Lafferty. (2014) High-density lipoprotein in uremic patients: metabolism, impairment, and therapy. International Urology and Nephrology 46:1, 27-39
CrossRef65
Baris Afsar, Kultigin Turkmen, Adrian Covic, Mehmet Kanbay. (2014) An Update on Coronary Artery Disease and Chronic Kidney Disease. International Journal of Nephrology 2014, 1-9
CrossRef66
Young-Ki Lee, Jieun Oh. (2014) Hemodialysis. Korean Journal of Medicine 86:2, 131
CrossRef67
Tamio Teramoto, Jun Sasaki, Shun Ishibashi, Sadatoshi Birou, Hiroyuki Daida, Seitaro Dohi, Genshi Egusa, Takafumi Hiro, Kazuhiko Hirobe, Mami Iida, Shinji Kihara, Makoto Kinoshita, Chizuko Maruyama, Takao Ohta, Tomonori Okamura, Shizuya Yamashita, Masayuki Yokode, Koutaro Yokote. (2014) Chronic Kidney Disease. Journal of Atherosclerosis and Thrombosis 21:3, 173-174
CrossRef68
Matthew I. Tomey, Jonathan A. Winston. (2014) Cardiovascular Pathophysiology in Chronic Kidney Disease: Opportunities to Transition from Disease to Health. Annals of Global Health 80:1, 69-76
CrossRef69
Marcello Bertoluci, Augusto Pimazoni-Netto, Antonio Pires, Antonio Pesaro, Beatriz D Schaan, Bruno Caramelli, Carisi Polanczyk, Carlos Vicente Júnior, Danielle M Gualandro, Domingos Malerbi, Emilio Moriguchi, Flavio Antonio Borelli, João Eduardo Salles, José Júnior, Luis Rohde, Luis H Canani, Luiz Antonio Cesar, Marcos Tambascia, Maria Zanella, Miguel Gus, Rafael Scheffel, Raul dos Santos. (2014) Diabetes and cardiovascular disease: from evidence to clinical practice – position statement 2014 of Brazilian Diabetes Society. Diabetology & Metabolic Syndrome 6:1, 58
CrossRef70
Michelle C Mann, Derek V Exner, Brenda R Hemmelgarn, David A Hanley, Tanvir C Turin, Jennifer M MacRae, Sofia B Ahmed. (2014) The VITAH Trial Vitamin D supplementation and cardiac autonomic tone in hemodialysis: a blinded, randomized controlled trial. BMC Nephrology 15:1, 129
CrossRef71
Chia-Hsuin Chang, Yen-Chieh Lee, Chia-Ti Tsai, Sheng-Nan Chang, Yu-Heng Chung, Min-Shung Lin, Jou-Wei Lin, Mei-Shu Lai. (2014) Continuation of statin therapy and a decreased risk of atrial fibrillation/flutter in patients with and without chronic kidney disease. Atherosclerosis 232:1, 224-230
CrossRef72
Aleksandra M. Ignjatović, Tatjana P. Cvetković, Radmila M. Pavlović, Vidojko M. Đorđević, Zoran G. Milošević, Vidosava B. Đorđević, Dušica D. Pavlović, Ivana R. Stojanović, Dragan Bogdanović. (2013) Endothelial dysfunction, inflammation and malnutrition markers as predictors of mortality in dialysis patients: multimarker approach. International Urology and Nephrology 45:6, 1715-1724
CrossRef73
Vasil Peev, Ali Nayer, Gabriel Contreras. (2013) Dyslipidemia, malnutrition, inflammation, cardiovascular disease and mortality in chronic kidney disease. Current Opinion in Lipidology1
CrossRef74
DIMITRIOS POULIKAKOS, DEBASISH BANERJEE, MAREK MALIK. (2013) Risk of Sudden Cardiac Death in Chronic Kidney Disease. Journal of Cardiovascular Electrophysiologyn/a-n/a
CrossRef75
Jaakko Helve, Reijo Sund, Mikko Haapio, Per-Henrik Groop, Carola Grönhagen-Riska, Patrik Finne. (2013) Medication among patients with type 1 diabetes and predialytic renal disease. Diabetes Research and Clinical Practice
CrossRef76
Maciej Banach, . (2013) Statins in patients with chronic kidney disease – an attempt at recommendations. Current Medical Research and Opinion 29:11, 1419-1422
CrossRef77
(2013) Chapter 2: Pharmacological cholesterol-lowering treatment in adults. Kidney International Supplements 3:3, 271-279
CrossRef78
J. Mihm, Ö. Uslu, U. Sester. (2013) Dysurische Beschwerden und Flankenschmerz bei dialysepflichtiger Patientin mit Diabetes mellitus. Der Nephrologe 8:6, 516-518
CrossRef79
Alfonso M. Cueto-Manzano, Juan R. Ángel-Zúñiga, Gabina Ornelas-Carrillo, E. Rojas-Campos, Héctor R. Martínez-Ramírez, Laura Cortés-Sanabria. (2013) Anti-Inflammatory Interventions in End-Stage Renal Disease: A Randomized, Double-Blinded, Controlled and Crossover Clinical Trial on the Use of Pravastatin in Continuous Ambulatory Peritoneal Dialysis. Archives of Medical Research
CrossRef80
Ricardo Gómez-Huelgas, Alberto Martínez-Castelao, Sara Artola, José Luis Górriz, Edelmiro Menéndez. (2013) Tratamiento de la diabetes tipo 2 en el paciente con enfermedad renal crónica. Medicina Clínica
CrossRef81
Paul M Ridker, Nancy R Cook. (2013) Statins: new American guidelines for prevention of cardiovascular disease. The Lancet 382:9907, 1762-1765
CrossRef82
Christoph Wanner, Kai-Renke Schmidt, Vera Krane. (2013) Results of the 4D study: ten years of follow-up?. Clinical and Experimental Nephrology
CrossRef83
N. Chen, X. Wu, X. Ding, C. Mei, P. Fu, G. Jiang, X. Li, J. Chen, B. Liu, Y. La, F. Hou, Z. Ni, J. Fu, C. Xing, X. Yu, C. Huang, L. Zuo, L. Wang, J. Hunter, M. Dillon, M. Plone, J. Neylan. (2013) Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study. Nephrology Dialysis Transplantation
CrossRef84
Chin-Chou Huang, Wan-Leong Chan, Yu-Chun Chen, Tzeng-Ji Chen, Chia-Min Chung, Po-Hsun Huang, Shing-Jong Lin, Jaw-Wen Chen, Hsin-Bang Leu. (2013) The beneficial effects of statins in patients undergoing hemodialysis. International Journal of Cardiology 168:4, 4155-4159
CrossRef85
Suma Vupputuri, Teresa M. Kimes, Michael O. Calloway, Jennifer B. Christian, David Bruhn, Alan A. Martin, Gregory A. Nichols. (2013) The economic burden of progressive chronic kidney disease among patients with type 2 diabetes. Journal of Diabetes and its Complications
CrossRef86
Tetsuo Shoji. (2013) Serum lipids and prevention of atherosclerotic cardiovascular events in hemodialysis patients. Clinical and Experimental Nephrology
CrossRef87
Suetonia C Palmer, Sankar D Navaneethan, Jonathan C Craig, David W Johnson, Vlado Perkovic, Sagar U Nigwekar, Jorgen Hegbrant, Giovanni FM Strippoli, Giovanni FM Strippoli. HMG CoA reductase inhibitors (statins) for dialysis patients. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2013.
CrossRef88
Suguru Yamamoto, Valentina Kon. (2013) Chronic kidney disease induced dysfunction of high density lipoprotein. Clinical and Experimental Nephrology
CrossRef89
Ziad A Massy, Dick de Zeeuw. (2013) LDL cholesterol in CKD—to treat or not to treat?. Kidney International 84:3, 451-456
CrossRef90
C. P. Kovesdy, L. D. Quarles. (2013) Fibroblast growth factor-23: what we know, what we don't know, and what we need to know. Nephrology Dialysis Transplantation 28:9, 2228-2236
CrossRef91
Tanja Hojs Fabjan, Radovan Hojs. (2013) Stroke and renal dysfunction. European Journal of Internal Medicine
CrossRef92
A. Olyaei, J. L. Steffl, J. MacLaughlan, M. Trabolsi, S. P. Quadri, I. Abbasi, E. Lerma. (2013) HMG-CoA Reductase Inhibitors in Chronic Kidney Disease. American Journal of Cardiovascular Drugs
CrossRef93
Nosratola D. Vaziri. (2013) Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease. Clinical and Experimental Nephrology
CrossRef94
J. A. Beckman, F. Paneni, F. Cosentino, M. A. Creager. (2013) Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. European Heart Journal 34:31, 2444-2452
CrossRef95
Debra L. Weinstein, Laura A. Williams, Dawn M. Carlson, Maureen T. Kelly, Kim M. Burns, Carolyn M. Setze, Aditya Lele, James C. Stolzenbach. (2013) A Randomized, Double-Blind Study of Fenofibric Acid Plus Rosuvastatin Compared With Rosuvastatin Alone in Stage 3 Chronic Kidney Disease. Clinical Therapeutics 35:8, 1186-1198
CrossRef96
Yuan Cheng, Tianlei Cui, Ping Fu, Fang Liu, Li Zhou. (2013) Dyslipidemia Is Associated With Tunneled-Cuffed Catheter-Related Central Venous Thrombosis in Hemodialysis Patients: A Retrospective, Multicenter Study. Artificial Organs 37:8, E155-E161
CrossRef97
James Barnett, Adie Viljoen, Anthony S. Wierzbicki. (2013) The Need for Combination Drug Therapies in Patients with Complex Dyslipidemia. Current Cardiology Reports 15:8,
CrossRef98
Kunitoshi Iseki. (2013) Nephrology for the people: Presidential Address at the 42nd Regional Meeting of the Japanese Society of Nephrology in Okinawa 2012. Clinical and Experimental Nephrology 17:4, 480-487
CrossRef99
Jennifer F. T. Teng, Tara Gomes, Ximena Camacho, Scott Grundy, David N. Juurlink, Muhammad M. Mamdani. (2013) Impact of the JUPITER Trial on Statin Prescribing for Primary Prevention. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapyn/a-n/a
CrossRef100
V. S. Stel, F. W. Dekker, C. Zoccali, K. J. Jager. (2013) Instrumental variable analysis. Nephrology Dialysis Transplantation 28:7, 1694-1699
CrossRef101
A. S. Wierzbicki. (2013) All at sea: new lipid-lowering drug trials continue to disappoint. International Journal of Clinical Practice 67:7, 595-598
CrossRef102
Anthony S. Wierzbicki, Adie Viljoen, Timothy C. Hardman, Dimitri P. Mikhailidis. (2013) New therapies to reduce low-density lipoprotein cholesterol. Current Opinion in Cardiology 28:4, 452-457
CrossRef103
Pierre Delanaye, Jean-Marie Krzesinski, Etienne Cavalier. (2013) EVOLVE : entre déception et optimisme. Néphrologie & Thérapeutique 9:4, 241-245
CrossRef104
F. Locatelli, N. Dimkovic, G. Spasovski. (2013) Evaluation of colestilan in chronic kidney disease dialysis patients with hyperphosphataemia and dyslipidaemia: a randomized, placebo-controlled, multiple fixed-dose trial. Nephrology Dialysis Transplantation 28:7, 1874-1888
CrossRef105
Jane Stock. (2013) HDL function and cardiovascular risk: Debate continues…. Atherosclerosis 229:1, 38-41
CrossRef106
Mieczysław Litwin, Anna Niemirska. (2013) Metabolic syndrome in children with chronic kidney disease and after renal transplantation. Pediatric Nephrology
CrossRef107
C. Wanner. (2013) Chronic kidney disease and statin therapy: to treat or not to treat?. European Heart Journal 34:24, 1772-1774
CrossRef108
W. Hou, J. Lv, V. Perkovic, L. Yang, N. Zhao, M. J. Jardine, A. Cass, H. Zhang, H. Wang. (2013) Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. European Heart Journal 34:24, 1807-1817
CrossRef109
Adeera Levin, William Lancashire, Robert G Fassett. (2013) Targets, trends, excesses, and deficiencies: refocusing clinical investigation to improve patient outcomes. Kidney International 83:6, 1001-1009
CrossRef110
Yu-Heng Chung, Yen-Chieh Lee, Chia-Hsuin Chang, Min-Shung Lin, Jou-Wei Lin, Mei-Shu Lai. (2013) Statins of high versus low cholesterol-lowering efficacy and the development of severe renal failure. Pharmacoepidemiology and Drug Safety 22:6, 583-592
CrossRef111
Marcin Barylski, Shekoufeh Nikfar, Dimitri P. Mikhailidis, Peter P. Toth, Pooneh Salari, Kausik K. Ray, Michael J. Pencina, Manfredi Rizzo, Jacek Rysz, Mohammad Abdollahi, Stephen J. Nicholls, Maciej Banach. (2013) Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy—A meta-analysis of 11 randomized controlled trials involving 21,295 participants. Pharmacological Research 72, 35-44
CrossRef112
K. Iseki, H. Arima, K. Kohagura, I. Komiya, S. Ueda, K. Tokuyama, Y. Shiohira, H. Uehara, S. Toma, , N. Tomiyama, H. Arima, S. Chinen, K. Tokashiki, A. Hirano-Nakasone, C. Nohara, S. Ueda, S. Ueda, K. Kohagura, S. Toma, T. Tana, A. Higa, M. Yamazato, Y. Ishida, K. Tokuyama, N. Nagayoshi, S. Miyagi, T. Asato, R. Kobayashi, Y. Shiohira, T. Yonaha, Y. Uezu, N. Kuwae, S. Nakasato, Y. Oshiro, K. Nashiro, T. Asato, H. Katsuren, H. Kagawa, K. Naika-Geka, T. Higa, M. Ikema, K. Akamine, M. Nishihira, M. Jahana, C. Imai, T. Yonaha, M. Ikemura, M. Uechi, M. Yamazato, K. Yoshihara, M. Arakaki, K. Iha, H. Afuso, S. Kiyuna, K. Shiroma, T. Miyara, M. Itokazu, T. Naka, S. Naka, E. Yamaguchi, Y. Uechi, T. Kowatari, H. Yamada, S. Yoshi, H. Sunagawa, M. Tozawa, M. Uechi, M. Adaniya, H. Afuso, H. Uehara, H. Miyazato, C. Sakuda, T. Taminato, H. Uchima, Y. Nakasone, T. Funakoshi, M. Nakazato, N. Nagata, S. Miyazato, H. Katsuren, T. Miyagi, H. Hirano, K. Iwashiro, T. Sunagawa, H. Yoshida, Y. Oshiro, T. Shimabukuro, T. Oura, H. Henzan, I. Kyan, S. Maeshiro, T. Wake, S. Tagawa, T. Inoue, T. Tokashiki, H. Ishii, S. Miyagi, S. Takishita, S. Saito, K. Shimizu, Y. Ohya, F. Barzi. (2013) Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial. Nephrology Dialysis Transplantation 28:6, 1579-1589
CrossRef113
Karthiek R. Narala, Sohail Hassan, Thomas A. LaLonde, Peter A. McCullough. (2013) Management of Coronary Atherosclerosis and Acute Coronary Syndromes in Patients With Chronic Kidney Disease. Current Problems in Cardiology 38:5, 165-206
CrossRef114
Amer K. Ardati, Bertram Pitt, Dean E. Smith, Herbert D. Aronow, David Share, Mauro Moscucci, Stanley Chetcuti, P. Michael Grossman, Hitinder S. Gurm. (2013) Current medical management of stable coronary artery disease before and after elective percutaneous coronary intervention. American Heart Journal 165:5, 778-784
CrossRef115
Tara I. Chang, Thomas K. Leong, Dhruv S. Kazi, Hon S. Lee, Mark A. Hlatky, Alan S. Go. (2013) Comparative effectiveness of coronary artery bypass grafting and percutaneous coronary intervention for multivessel coronary disease in a community-based population with chronic kidney disease. American Heart Journal 165:5, 800-808.e2
CrossRef116
Michael S. Kostapanos, Matilda Florentin, Moses S. Elisaf. (2013) Fenofibrate and the kidney: an overview. European Journal of Clinical Investigation 43:5, 522-531
CrossRef117
Valentina Kon, T. Alp Ikizler, Sergio Fazio. (2013) Importance of high-density lipoprotein quality. Current Opinion in Nephrology and Hypertension 22:3, 259-265
CrossRef118
Dragana Nikolic, Shekoufeh Nikfar, Pooneh Salari, Manfredi Rizzo, Kausik K. Ray, Michael J. Pencina, Dimitri P. Mikhailidis, Peter P. Toth, Stephen J. Nicholls, Jacek Rysz, Mohammad Abdollahi, Maciej Banach, . (2013) Effects of statins on lipid profile in chronic kidney disease patients: a meta-analysis of randomized controlled trials. Current Medical Research and Opinion 29:5, 435-451
CrossRef119
P. M. Ridker, J. J. P. Kastelein, J. Genest, W. Koenig. (2013) C-reactive protein and cholesterol are equally strong predictors of cardiovascular risk and both are important for quality clinical care. European Heart Journal 34:17, 1258-1261
CrossRef120
Mario Bonomini, Lorenzo Di Liberato, Goffredo Del Rosso, Antonio Stingone, Giancarlo Marinangeli, Agostino Consoli, Silvio Bertoli, Amedeo De Vecchi, Emanuele Bosi, Roberto Russo, Roberto Corciulo, Loreto Gesualdo, Francesco Giorgino, Paolo Cerasoli, Augusto Di Castelnuovo, Maria Pia Monaco, Ty Shockley, Claudia Rossi, Arduino Arduini. (2013) Effect of an l-Carnitine–Containing Peritoneal Dialysate on Insulin Sensitivity in Patients Treated With CAPD: A 4-Month, Prospective, Multicenter Randomized Trial. American Journal of Kidney Diseases
CrossRef121
Yuya Matsue, Makoto Suzuki, Wataru Nagahori, Masakazu Ohno, Akihiko Matsumura, Yuji Hashimoto. (2013) Beta-blocker prevents sudden cardiac death in patients with hemodialysis. International Journal of Cardiology 165:3, 519-522
CrossRef122
Rajesh K Aggarwal, Refai Showkathali. (2013) Rosuvastatin calcium in acute coronary syndromes. Expert Opinion on Pharmacotherapy1-13
CrossRef123
Eyad Alhaj, Nehad Alhaj, Ifad Rahman, Tariq O. Niazi, Robert Berkowitz, Marc Klapholz. (2013) Uremic Cardiomyopathy: An Underdiagnosed Disease. Congestive Heart Failuren/a-n/a
CrossRef124
Staci Valley, Julie Wright-Nunes. (2013) Management Considerations for the Hospitalist Caring for Patients with End-Stage Renal Disease. Hospital Medicine Clinics 2:2, e209-e226
CrossRef125
R. K. Patel, K. K. Stevens, A. G. Jardine. (2013) Sleep apnoea and the potential benefits of a good night's sleep in patients receiving maintenance dialysis. Nephrology Dialysis Transplantation 28:4, 777-778
CrossRef126
Bruce K. Birmingham, Suzanne K. Swan, Tom Puchalski, Pat Mitchell, Connie Azumaya, Julie Zalikowski, Yi Wang. (2013) Pharmacokinetic and Pharmacodynamic Profile of Rosuvastatin in Patients with End-Stage Renal Disease on Chronic Haemodialysis. Clinical Drug Investigation 33:4, 233-241
CrossRef127
H. Gohlke, C. Albus, G. Bönner, H. Darius, S. Eckert, C. Gohlke-Bärwolf, D. Gysan, H. Hahmann, M. Halle, R. Hambrecht, P. Mathes, H.-G. Predel, G. Sauer †, C. Schacky, G. Schuler, J. Siegrist, J. Thiery, D. Tschöpe, H. Völler, A. Wirth. (2013) Empfehlungen der Projektgruppe Prävention der DGK zur risikoadjustierten Prävention von Herz- und Kreislauferkrankungen. Der Kardiologe 7:2, 141-156
CrossRef128
Sudarshan Balla, Maen B Nusair, Martin A Alpert. (2013) Risk factors for atherosclerosis in patients with chronic kidney disease: recognition and management. Current Opinion in Pharmacology 13:2, 192-199
CrossRef129
A. H. Berg, C. Drechsler, J. Wenger, R. Buccafusca, T. Hod, S. Kalim, W. Ramma, S. M. Parikh, H. Steen, D. J. Friedman, J. Danziger, C. Wanner, R. Thadhani, S. A. Karumanchi. (2013) Carbamylation of Serum Albumin as a Risk Factor for Mortality in Patients with Kidney Failure. Science Translational Medicine 5:175, 175ra29-175ra29
CrossRef130
Kevin F. Erickson, Sohan Japa, Douglas K. Owens, Glenn M. Chertow, Alan M. Garber, Jeremy D. Goldhaber-Fiebert. (2013) Cost-Effectiveness of Statins for Primary Cardiovascular Prevention in Chronic Kidney Disease. Journal of the American College of Cardiology 61:12, 1250-1258
CrossRef131
Joost Besseling, Julian Capelleveen, John J. P. Kastelein, G. Kees Hovingh. (2013) LDL Cholesterol Goals in High-Risk Patients: How Low Do We Go and How Do We Get There?. Drugs 73:4, 293-301
CrossRef132
Bertram L. Kasiske, David C. Wheeler. (2013) The Management of Dyslipidemia in CKD: New Analyses of an Expanding Dataset. American Journal of Kidney Diseases 61:3, 371-374
CrossRef133
Nael Hawwa, Martin J. Schreiber, W. H. Wilson Tang. (2013) Pharmacologic Management of Chronic Reno-Cardiac Syndrome. Current Heart Failure Reports 10:1, 54-62
CrossRef134
Mark R. Kahn, Michael J. Robbins, Michael C. Kim, Valentin Fuster. (2013) Management of cardiovascular disease in patients with kidney disease. Nature Reviews Cardiology 10:5, 261-273
CrossRef135
Tzu-Hsien Tsai, Kuo-Ho Yeh, Cheuk-Kwan Sun, Cheng-Hsu Yang, Shyh-Ming Chen, Chi-Ling Hang, Chien-Jen Chen, Sheng-Ying Chung, Yung-Lung Chen, Chiung-Jen Wu, Hsuen-Wen Chang, Hon-Kan Yip. (2013) Estimated Glomerular Filtration Rate as a Useful Predictor of Mortality in Patients With Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. The American Journal of the Medical Sciences 345:2, 104-111
CrossRef136
Min Jun, Meg J. Jardine, Nicholas Gray, Rosemary Masterson, Peter G. Kerr, John W.M. Agar, Carmel M. Hawley, Carolyn van Eps, Alan Cass, Martin Gallagher, Vlado Perkovic. (2013) Outcomes of Extended-Hours Hemodialysis Performed Predominantly at Home. American Journal of Kidney Diseases 61:2, 247-253
CrossRef137
Yen-Ta Chen, Ben-Chung Cheng, Sheung-Fat Ko, Chih-Hung Chen, Tzu-Hsien Tsai, Steve Leu, Hsueh-Wen Chang, Sheng-Ying Chung, Sarah Chua, Kuo-Ho Yeh, Yung-Lung Chen, Hon-Kan Yip. (2013) Value and level of circulating endothelial progenitor cells, angiogenesis factors and mononuclear cell apoptosis in patients with chronic kidney disease. Clinical and Experimental Nephrology 17:1, 83-91
CrossRef138
Alberico Catapano, Peter P Toth, Joanne E Tomassini, Andrew M Tershakovec. (2013) The efficacy and safety of ezetimibe coadministered with statin therapy in various patient groups. Clinical Lipidology 8:1, 13-41
CrossRef139
Arjan J. Kwakernaak, Gilles Lambert, Maartje C.J. Slagman, Femke Waanders, Gozewijn D. Laverman, Francine Petrides, Bert D. Dikkeschei, Gerjan Navis, Robin P.F. Dullaart. (2013) Proprotein convertase subtilisin–kexin type 9 is elevated in proteinuric subjects: Relationship with lipoprotein response to antiproteinuric treatment. Atherosclerosis 226:2, 459-465
CrossRef140
S. Sharma, K. Farrington, R. Kozarski, C. Christopoulos, M. Niespialowska-Steuden, D. Moffat, D. A. Gorog. (2013) Impaired thrombolysis: a novel cardiovascular risk factor in end-stage renal disease. European Heart Journal 34:5, 354-363
CrossRef141
Martin Busch. Cardiovascular Disease in Diabetic Nephropathy: Pathophysiology and Treatment. In: Diabetes and Kidney Disease. Wiley-Blackwell, 2013:83-100.
CrossRef142
Muriel Ghosn, Fuad N. Ziyadeh. Treatment of the Patient with End-Stage Diabetic Nephropathy. In: Diabetes and Kidney Disease. Wiley-Blackwell, 2013:215-231.
CrossRef143
Christoph Wanner. Statin Therapy in Patients with Diabetic Nephropathy. In: Diabetes and Kidney Disease. Wiley-Blackwell, 2013:101-115.
CrossRef144
William F Keane, Joanne E Tomassini, David R Neff. (2013) Lipid Abnormalities in Patients with Chronic Kidney Disease: Implications for the Pathophysiology of Atherosclerosis. Journal of Atherosclerosis and Thrombosis 20:2, 123-133
CrossRef145
Csaba Kovesdy, Kamyar Kalantar-Zadeh. Protein-Energy Wasting as a Risk Factor of Morbidity and Mortality in Chronic Kidney Disease. In: Nutritional Management of Renal Disease. Elsevier, 2013:171-195.
CrossRef146
Michel de Lorgeril, Patricia Salen, Pascal Defaye, Mikael Rabaeus. (2013) Recent findings on the health effects of omega-3 fatty acids and statins, and their interactions: do statins inhibit omega-3?. BMC Medicine 11:1, 5
CrossRef147
Daisuke Koya, Vito M Campese. (2013) Statin Use in Patients with Diabetes and Kidney Disease: The Japanese Experience. Journal of Atherosclerosis and Thrombosis 20:5, 407-424
CrossRef148
Jung Tak Park, Hyung Jung Oh, Shin-Wook Kang. (2013) Cardiovascular disease in end-stage renal disease. Journal of the Korean Medical Association 56:7, 576
CrossRef149
Nosratola D. Vaziri. Altered Lipid Metabolism and Serum Lipids in Kidney Disease and Kidney Failure. In: Nutritional Management of Renal Disease. Elsevier, 2013:31-48.
CrossRef150
(2013) Chapter 4: Other complications of CKD: CVD, medication dosage, patient safety, infections, hospitalizations, and caveats for investigating complications of CKD. Kidney International Supplements 3:1, 91-111
CrossRef151
Joanna Dunlop, Alain Vandal, Janak de Zoysa, Ruvin Gabriel, Imad Haloob, Christopher Hood, Philip Matheson, David Owen Ross McGregor, Kannaiyan Rabindranath, David Semple, Mark Marshall. (2013) Rationale and design of the Sodium Lowering In Dialysate (SoLID) trial: a randomised controlled trial of low versus standard dialysate sodium concentration during hemodialysis for regression of left ventricular mass. BMC Nephrology 14:1, 149
CrossRef152
Neil J. Stone. Drugs for Elevated Low-Density Lipoprotein Cholesterol. In: Cardiovascular Therapeutics: A Companion to Braunwald's Heart Disease. Elsevier, 2013:421-433.
CrossRef153
Andreas Schneider, Alan G. Jardine, Markus P. Schneider, Hallvard Holdaas, Ingar Holme, Bengt C. Fellstroem, Faiez Zannad, Roland E. Schmieder. (2013) Determinants of Cardiovascular Risk in Haemodialysis Patients: Post hoc Analyses of the AURORA Study. American Journal of Nephrology 37:2, 144-151
CrossRef154
R. Hajhosseiny, K. Khavandi, D. J. Goldsmith. (2013) Cardiovascular disease in chronic kidney disease: untying the Gordian knot. International Journal of Clinical Practice 67:1, 14-31
CrossRef155
Elaine Ku, Vito Campese. (2013) Is Lipid Management Effective for All Stages of CKD?. Blood Purification 35:1-3, 26-30
CrossRef156
Sang Yup Lim. (2013) Role of Statins in Coronary Artery Disease. Chonnam Medical Journal 49:1, 1
CrossRef157
Willibald Hochholzer, Robert P. Giugliano. (2013) Does it Make Sense to Combine Statins with Other Lipid-Altering Agents Following AIM-HIGH, SHARP and ACCORD?. Current Atherosclerosis Reports 15:1,
CrossRef158
Pranav S. Garimella, Daniel E. Weiner, Mark J. Sarnak. Prevention and Management of Cardiovascular Disease in Kidney Disease and Kidney Failure. In: Nutritional Management of Renal Disease. Elsevier, 2013:123-135.
CrossRef159
Andreas Kuznik, Jack Mardekian, Lisa Tarasenko. (2013) Evaluation of cardiovascular disease burden and therapeutic goal attainment in US adults with chronic kidney disease: an analysis of national health and nutritional examination survey data, 2001–2010. BMC Nephrology 14:1, 132
CrossRef160
Steven Grangé, Mélanie Hanoy, Frank Le Roy, Dominique Guerrot, Michel Godin. (2013) Monitoring of hemodialysis quality-of-care indicators: why is it important?. BMC Nephrology 14:1, 109
CrossRef161
Nosratola D. Vaziri, Keith C. Norris. (2013) Reasons for the Lack of Salutary Effects of Cholesterol-Lowering Interventions in End-Stage Renal Disease Populations. Blood Purification 35:1-3, 31-36
CrossRef162
Peter Stenvinkel. (2013) Can Treating Persistent Inflammation Limit Protein Energy Wasting?. Seminars in Dialysis 26:1, 16-19
CrossRef163
(2013) Chapter 5: Referral to specialists and models of care. Kidney International Supplements 3:1, 112-119
CrossRef164
Juan Jesús Carrero, Peter Stenvinkel. Inflammation in Chronic Kidney Disease. In: Nutritional Management of Renal Disease. Elsevier, 2013:79-91.
CrossRef165
Eiichiro Kanda, Masumi Ai, Asami Iwamoto, Mitsuyo Okazaki, Yoshitaka Maeda, Sei Sasaki, Masayuki Yoshida. (2013) Relationship between Icodextrin use and decreased level of small low-density lipoprotein cholesterol fractioned by high-performance gel permeation chromatography. BMC Nephrology 14:1, 234
CrossRef166
Jwa-Kyung Kim, Young Rim Song, Min Gang Kim, Hyung Jik Kim, Sung Gyun Kim. (2013) Clinical significance of subclinical carotid atherosclerosis and its relationship with echocardiographic parameters in non-diabetic chronic kidney disease patients. BMC Cardiovascular Disorders 13:1, 96
CrossRef167
Darren Green, James P. Ritchie, Philip A. Kalra. (2013) Meta-Analysis of Lipid-Lowering Therapy in Maintenance Dialysis Patients. Nephron Clinical Practice 124:3-4, 209-217
CrossRef168
Tsuneo Takenaka, Hiroshi Takane, Tomohiro Kikuta, Yusuke Watanabe, Hiromichi Suzuki. (2013) Statin Improves Flow-Mediated Vasodilation in Chronic Kidney Diseases. International Journal of Hypertension 2013, 1-9
CrossRef169
The EVOLVE Trial Investigators. (2012) Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis. New England Journal of Medicine 367:26, 2482-2494
Free Full Text170
Elaine M Beller, Rashmi Balaram, Talvika Kooblal, Benita Thurairajah, Christine Sammartino, Yan T Lai, Elaine M Beller. Dietary interventions for lowering cholesterol in dialysis patients. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2012.
CrossRef171
Kelli King-Morris, T. Alp Ikizler. (2012) Insulin Resistance in Patients Undergoing Peritoneal Dialysis: Can We Improve It?. Cardiovascular Drugs and Therapy 26:6, 441-443
CrossRef172
(2012) Chapter 3: Blood pressure management in CKD ND patients without diabetes mellitus. Kidney International Supplements 2:5, 357-362
CrossRef173
, Joep Perk, Guy Backer, Helmut Gohlke, Ian Graham, Željko Reiner, W. M. Monique Verschuren, Christian Albus, Pascale Benlian, Gudrun Boysen, Renata Cifkova, Christi Deaton, Shah Ebrahim, Miles Fisher, Giuseppe Germano, Richard Hobbs, Arno Hoes, Sehnaz Karadeniz, Alessandro Mezzani, Eva Prescott, Lars Ryden, Martin Scherer, Mikko Syvänne, Wilma J. M. Scholte Reimer, Christiaan Vrints, David Wood, Jose Luis Zamorano, Faiez Zannad. (2012) European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012). International Journal of Behavioral Medicine 19:4, 403-488
CrossRef174
Soichiro Iimori, Yoshihiro Mori, Wataru Akita, Shigeru Takada, Tamaki Kuyama, Tsuyoshi Ohnishi, Satomi Shikuma, Junichi Ishigami, Masato Tajima, Tomoki Asai, Tomokazu Okado, Michio Kuwahara, Sei Sasaki, Yusuke Tsukamoto. (2012) Effects of sevelamer hydrochloride on mortality, lipid abnormality and arterial stiffness in hemodialyzed patients: a propensity-matched observational study. Clinical and Experimental Nephrology 16:6, 930-937
CrossRef175
Scott M. Grundy. (2012) Treatment Targets in the Management of Dyslipidemias: Which Targets in Whom?. Current Cardiology Reports 14:6, 692-700
CrossRef176
(2012) Chapter 1: Introduction. Kidney International Supplements 2:5, 343-346
CrossRef177
R. Kramann, J. Floege, M. Ketteler, N. Marx, V. M. Brandenburg. (2012) Medical options to fight mortality in end-stage renal disease: a review of the literature. Nephrology Dialysis Transplantation 27:12, 4298-4307
CrossRef178
Masahiro Natsuaki, Yutaka Furukawa, Takeshi Morimoto, Ryuzo Sakata, Takeshi Kimura. (2012) Renal Function and Effect of Statin Therapy on Cardiovascular Outcomes in Patients Undergoing Coronary Revascularization (from the CREDO-Kyoto PCI/CABG Registry Cohort-2). The American Journal of Cardiology 110:11, 1568-1577
CrossRef179
Christopher D. Owens. (2012) Statins and other agents for vascular inflammation. Journal of Vascular Surgery 56:6, 1799-1806
CrossRef180
Suguru Yamamoto, Patricia G. Yancey, T. Alp Ikizler, W. Gray Jerome, Ryohei Kaseda, Brian Cox, Aihua Bian, Ayumi Shintani, Agnes B. Fogo, MacRae F. Linton, Sergio Fazio, Valentina Kon. (2012) Dysfunctional High-Density Lipoprotein in Patients on Chronic Hemodialysis. Journal of the American College of Cardiology 60:23, 2372-2379
CrossRef181
James B. Wetmore, Jonathan D. Mahnken, Purna Mukhopadhyay, Qingjiang Hou, Edward F. Ellerbeck, Sally K. Rigler, John A. Spertus, Theresa I. Shireman. (2012) Geographic Variation in HMG-CoA Reductase Inhibitor Use in Dialysis Patients. Journal of General Internal Medicine 27:11, 1475-1483
CrossRef182
Nathan Birch, Jennifer Fillaus, Marius C. Florescu. (2012) The effect of statin therapy on the formation of arteriovenous fistula stenoses and the rate of reoccurrence of previously treated stenoses. Hemodialysis Internationaln/a-n/a
CrossRef183
Marius C. Florescu, Nathan Birch. (2012) Statin Therapy and Hemodialysis Vascular Access-Were We Bringing a Knife to a Gunfight and Were Hoping to Win?. Seminars in Dialysis 25:6, 700-702
CrossRef184
Aitor Arias Fernández, Artemio Álvarez Cosmea, Ana isabel Barrio Alonso, Luis Díaz González, Ana Laura Rivero Pérez. (2012) Colesterol de las lipoproteínas de baja densidad <70mg/dl en la enfermedad renal crónica. ¿Ficción o realidad?. Clínica e Investigación en Arteriosclerosis 24:6, 284-288
CrossRef185
Yelena Slinin, Areef Ishani, Thomas Rector, Patrick Fitzgerald, Roderick MacDonald, James Tacklind, Indulis Rutks, Timothy J. Wilt. (2012) Management of Hyperglycemia, Dyslipidemia, and Albuminuria in Patients With Diabetes and CKD: A Systematic Review for a KDOQI Clinical Practice Guideline. American Journal of Kidney Diseases 60:5, 747-769
CrossRef186
(2012) KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. American Journal of Kidney Diseases 60:5, 850-886
CrossRef187
Hallvard Holdaas, Alan Jardine. (2012) Chronic kidney disease: Do patients with CKD benefit from lipid-lowering therapy?. Nature Reviews Nephrology 8:12, 684-685
CrossRef188
Agata Kujawa-Szewieczek, Andrzej Więcek, Grzegorz Piecha. (2012) The lipid story in chronic kidney disease: a long story with a happy end?. International Urology and Nephrology
CrossRef189
Kazuhiko Tsuruya, Hideki Hirakata. (2012) Japanese Society for Dialysis Therapy Guidelines for Management of Cardiovascular Diseases in Patients on Chronic Hemodialysis. Therapeutic Apheresis and Dialysis 16:5, 384-386
CrossRef190
Dimitrios Kirmizis, Aikaterini Papagianni, Fani Dogrammatzi, Anna-Maria Belechri, Efstathios Alexopoulos, Georgios Efstratiadis, Dimitrios Memmos. (2012) The Effects of Vitamin E-Coated Membrane Dialyzer Compared to Simvastatin in Patients on Chronic Hemodialysis. Renal Failure 34:9, 1135-1139
CrossRef191
Hideki Hirakata, Kosaku Nitta, Masaaki Inaba, Tetsuo Shoji, Hideki Fujii, Shuzo Kobayashi, Kaoru Tabei, Nobuhiko Joki, Hiroki Hase, Masato Nishimura, Shigeyuki Ozaki, Yuji Ikari, Yoshitaka Kumada, Kazuhiko Tsuruya, Shouichi Fujimoto, Tohru Inoue, Hiroyoshi Yokoi, Sumio Hirata, Kazuaki Shimamoto, Kiyotaka Kugiyama, Takashi Akiba, Kunitoshi Iseki, Yoshiharu Tsubakihara, Tadashi Tomo, Tadao Akizawa. (2012) Japanese Society for Dialysis Therapy Guidelines for Management of Cardiovascular Diseases in Patients on Chronic Hemodialysis. Therapeutic Apheresis and Dialysis 16:5, 387-435
CrossRef192
Pranav S. Garimella, Peter D. Hart, Ann O'Hare, Stephanie DeLoach, Charles A. Herzog, Alan T. Hirsch. (2012) Peripheral Artery Disease and CKD: A Focus on Peripheral Artery Disease as a Critical Component of CKD Care. American Journal of Kidney Diseases 60:4, 641-654
CrossRef193
M. K. de Bie, M. G. Koopman, A. Gaasbeek, F. W. Dekker, A. C. Maan, C. A. Swenne, R. W. Scherptong, P. F. van Dessel, A. A. Wilde, M. J. Schalij, T. J. Rabelink, J. W. Jukema. (2012) Incremental prognostic value of an abnormal baseline spatial QRS-T angle in chronic dialysis patients. Europace
CrossRef194
Suetonia C Palmer, Kannaiyan S Rabindranath, Jonathan C Craig, Paul J Roderick, Francesco Locatelli, Giovanni FM Strippoli, Giovanni FM Strippoli. High-flux versus low-flux membranes for end-stage kidney disease. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2012.
CrossRef195
Jogchum Plat, Dieter Lutjohann, Ronald P. Mensink. (2012) What is the real meaning of increased serum plant sterol concentrations?. British Journal of Nutrition 108:05, 943-945
CrossRef196
TSUYOSHI NOZUE, SHINGO YAMAMOTO, SHINICHI TOHYAMA, KAZUKI FUKUI, SHIGEO UMEZAWA, YUKO ONISHI, TOMOYUKI KUNISHIMA, KIYOSHI HIBI, MITSUYASU TERASHIMA, ICHIRO MICHISHITA, . (2012) Impacts of estimated glomerular filtration rate on coronary atherosclerosis and plaque composition before and during statin therapy in patients with normal to mild renal dysfunction: Subanalysis of the TRUTH study. Nephrology 17:7, 628-635
CrossRef197
Darren Green, Rosica Panayotova, James P. Ritchie, Edmond O’Riordan, John McDonald. (2012) LIPID-LOWERING THERAPY IN CHRONIC KIDNEY DISEASE: IS THERE A ROLE FOR EZETIMIBE?. Journal of Renal Care 38:3, 138-146
CrossRef198
V. Bongard, J. Dallongeville, D. Arveiler, J.-B. Ruidavets, D. Cottel, A. Wagner, J. Ferrières. (2012) Estimation et caractérisation de l’insuffisance rénale chronique en France. Annales de Cardiologie et d'Angéiologie 61:4, 239-244
CrossRef199
Kosaku Nitta. (2012) Clinical assessment and management of dyslipidemia in patients with chronic kidney disease. Clinical and Experimental Nephrology 16:4, 522-529
CrossRef200
L. H. W. Gowdak, J. J. G. De Lima. (2012) Reply. Nephrology Dialysis Transplantation 27:8, 3371-3371
CrossRef201
Cristina Karohl, Paolo Raggi. (2012) Approach to Cardiovascular Disease Prevention in Patients With Chronic Kidney Disease. Current Treatment Options in Cardiovascular Medicine 14:4, 391-413
CrossRef202
G. H. Heine, S. Seiler, D. Fliser. (2012) FGF-23: the rise of a novel cardiovascular risk marker in CKD. Nephrology Dialysis Transplantation 27:8, 3072-3081
CrossRef203
JIN DENG, QIAOYUAN WU, YUNHUA LIAO, DONGMEI HUO, ZHENHUA YANG. (2012) Effect of statins on chronic inflammation and nutrition status in renal dialysis patients: A systematic review and meta-analysis. Nephrology 17:6, 545-551
CrossRef204
Keiji Kono, Hideki Fujii, Kentaro Nakai, Shunsuke Goto, Junya Shite, Ken-ichi Hirata, Masafumi Fukagawa, Shinichi Nishi. (2012) Composition and plaque patterns of coronary culprit lesions and clinical characteristics of patients with chronic kidney disease. Kidney International 82:3, 344-351
CrossRef205
(2012) The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. The Lancet 380:9841, 581-590
CrossRef206
Tanja Antunovic, Aleksandra Stefanovic, Marina Ratkovic, Branka Gledovic, Najdana Gligorovic-Barhanovic, Dragica Bozovic, Jasmina Ivanisevic, Milica Prostran, Marina Stojanov. (2012) High uric acid and low superoxide dismutase as possible predictors of all-cause and cardiovascular mortality in hemodialysis patients. International Urology and Nephrology
CrossRef207
Kristen L. Jablonski, Michel Chonchol. (2012) Cardiovascular disease: Should statin therapy be expanded in patients with CKD?. Nature Reviews Nephrology 8:8, 440-441
CrossRef208
Karl Winkler, Michael M. Hoffmann, Vera Krane, Christiane Drechsler, Christoph Wanner, . (2012) Lipoprotein-associated phospholipase A2 and outcome in patients with type 2 diabetes on haemodialysis. European Journal of Clinical Investigation 42:7, 693-701
CrossRef209
Kosmas I. Paraskevas, Anthony S. Wierzbicki, Dimitri P. Mikhailidis. (2012) Statins and noncardiac vascular disease. Current Opinion in Cardiology 27:4, 392-397
CrossRef210
T. Bejan-Angoulvant, C. Bergerot, L. Juillard, A. Mezergues, E. Morelon, C. Pouteil-Noble, X. Andre-Fouet, D. Angoulvant. (2012) Myocardial microvascular disease and major adverse cardiovascular events in patients with end-stage renal disease: rationale and design of the MICROCARD study. Nephrology Dialysis Transplantation 27:7, 2886-2891
CrossRef211
, J. Perk, G. De Backer, H. Gohlke, I. Graham, Z. Reiner, M. Verschuren, C. Albus, P. Benlian, G. Boysen, R. Cifkova, C. Deaton, S. Ebrahim, M. Fisher, G. Germano, R. Hobbs, A. Hoes, S. Karadeniz, A. Mezzani, E. Prescott, L. Ryden, M. Scherer, M. Syvanne, W. J. M. Scholte Op Reimer, C. Vrints, D. Wood, J. L. Zamorano, F. Zannad, , M. T. Cooney, , J. Bax, H. Baumgartner, C. Ceconi, V. Dean, C. Deaton, R. Fagard, C. Funck-Brentano, D. Hasdai, A. Hoes, P. Kirchhof, J. Knuuti, P. Kolh, T. McDonagh, C. Moulin, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, M. Tendera, A. Torbicki, A. Vahanian, S. Windecker, , C. Funck-Brentano, P. A. Sirnes, V. Aboyans, E. A. Ezquerra, C. Baigent, C. Brotons, G. Burell, A. Ceriello, J. De Sutter, J. Deckers, S. Del Prato, H.-C. Diener, D. Fitzsimons, Z. Fras, R. Hambrecht, P. Jankowski, U. Keil, M. Kirby, M. L. Larsen, G. Mancia, A. J. Manolis, J. McMurray, A. Pajak, A. Parkhomenko, L. Rallidis, F. Rigo, E. Rocha, L. M. Ruilope, E. van der Velde, D. Vanuzzo, M. Viigimaa, M. Volpe, O. Wiklund, C. Wolpert. (2012) European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European Heart Journal 33:13, 1635-1701
CrossRef212
Csaba P. Kovesdy, Kamyar Kalantar-Zadeh. (2012) Accuracy and Limitations of the Diagnosis of Malnutrition in Dialysis Patients. Seminars in Dialysis 25:4, 423-427
CrossRef213
Roger E. Morgan, Stuart E. Campbell, Christine Y. Yu, Craig A. Sponseller, Heather A. Muster. (2012) Comparison of the Safety, Tolerability, and Pharmacokinetic Profile of a Single Oral Dose of Pitavastatin 4 mg in Adult Subjects With Severe Renal Impairment Not on Hemodialysis Versus Healthy Adult Subjects. Journal of Cardiovascular Pharmacology 60:1, 42-48
CrossRef214
G. M. Chertow, R. Correa-Rotter, G. A. Block, T. B. Drueke, J. Floege, W. G. Goodman, C. A. Herzog, Y. Kubo, G. M. London, K. W. Mahaffey, T.-C. Mix, S. M. Moe, D. C. Wheeler, P. S. Parfrey. (2012) Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial. Nephrology Dialysis Transplantation 27:7, 2872-2879
CrossRef215
Jai Prakash. (2012) Management of dyslipidemia in CKD, dialysis and renal transplant recipient. Clinical Queries: Nephrology
CrossRef216
My Svensson, Alan Jardine, Bengt Fellström, Hallvard Holdaas. (2012) Prevention of cardiovascular disease after renal transplantation. Current Opinion in Organ Transplantation1
CrossRef217
Theodoros Eleftheriadis, Georgia Antoniadi, Vassilios Liakopoulos, Georgios Pissas, Spyridon Arampatzis, Theodora Sparopoulou, Grammati Galaktidou, Ioannis Stefanidis. (2012) Perilipin-1 in Hemodialyzed Patients: Association With History of Coronary Heart Disease and Lipid Profile. Therapeutic Apheresis and Dialysisno-no
CrossRef218
Krista L. Lentine, Salvatore P. Costa, Matthew R. Weir, John F. Robb, Lee A. Fleisher, Bertram L. Kasiske, Robert L. Carithers, Michael Ragosta, Kline Bolton, Andrew D. Auerbach, Kim A. Eagle. (2012) Cardiac Disease Evaluation and Management Among Kidney and Liver Transplantation Candidates. Journal of the American College of Cardiology 60:5, 434-480
CrossRef219
Sheila A Doggrell. (2012) The ezetimibe controversy – can this be resolved by comparing the clinical trials with simvastatin and ezetimibe alone and together?. Expert Opinion on Pharmacotherapy 13:10, 1469-1480
CrossRef220
Joep Perk, Guy De Backer, Helmut Gohlke, Ian Graham, Željko Reiner, W.M. Monique Verschuren, Christian Albus, Pascale Benlian, Gudrun Boysen, Renata Cifkova, Christi Deaton, Shah Ebrahim, Miles Fisher, Giuseppe Germano, Richard Hobbs, Arno Hoes, Sehnaz Karadeniz, Alessandro Mezzani, Eva Prescott, Lars Ryden, Martin Scherer, Mikko Syvänne, Wilma J.M. Scholte Op Reimer, Christiaan Vrints, David Wood, Jose Luis Zamorano, Faiez Zannad. (2012) European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Atherosclerosis 223:1, 1-68
CrossRef221
Eun Hui Bae, Sang Yup Lim, Kyung Hoon Cho, Joon Seok Choi, Chang Seong Kim, Jeong Woo Park, Seong Kwon Ma, Myung Ho Jeong, Soo Wan Kim. (2012) GFR and Cardiovascular Outcomes After Acute Myocardial Infarction: Results From the Korea Acute Myocardial Infarction Registry. American Journal of Kidney Diseases 59:6, 795-802
CrossRef222
Tanuj Bhatia, Aditya Kapoor. (2012) Chronic kidney disease and its adverse cardiovascular associations. Clinical Queries: Nephrology
CrossRef223
Steen E. Husted, Robert F. Storey, Kevin Bliden, Udaya S. Tantry, Lene Høimark, Kathleen Butler, Cheryl Wei, Renli Teng, Paul A. Gurbel. (2012) Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Stable Coronary Artery Disease. Clinical Pharmacokinetics 51:6, 397-409
CrossRef224
Mark Jenkins, David Goldsmith. (2012) Statins and kidney disease. Current Opinion in Cardiology1
CrossRef225
Sang Yup Lim, Eun Hui Bae, Joon Seok Choi, Chang Seong Kim, Jeong Woo Park, Seong Kwon Ma, Myung Ho Jeong, Soo Wan Kim. (2012) Effect on Short- and Long-Term Major Adverse Cardiac Events of Statin Treatment in Patients With Acute Myocardial Infarction and Renal Dysfunction. The American Journal of Cardiology 109:10, 1425-1430
CrossRef226
Shelley R. Salpeter, Esther J. Luo, Dawn S. Malter, Brad Stuart. (2012) Systematic Review of Noncancer Presentations with a Median Survival of 6 Months or Less. The American Journal of Medicine 125:5, 512.e1-512.e16
CrossRef227
Mark R. Marshall, Joanna L. Dunlop. (2012) Are Dialysate Sodium Levels Too High?. Seminars in Dialysis 25:3, 277-283
CrossRef228
Anthony S Wierzbicki, Timothy C Hardman, Adie Viljoen. (2012) Inhibition of pre-protein convertase serine kexin-9 (PCSK-9) as a treatment for hyperlipidaemia. Expert Opinion on Investigational Drugs 21:5, 667-676
CrossRef229
Diane L. Frankenfield, Eric D. Weinhandl, Christopher A. Powers, Benjamin L. Howell, Charles A. Herzog, Wendy L. St. Peter. (2012) Utilization and Costs of Cardiovascular Disease Medications in Dialysis Patients in Medicare Part D. American Journal of Kidney Diseases 59:5, 670-681
CrossRef230
I. Holme, B. C. Fellström, A. G. Jardin, R. E. Schmieder, F. Zannad, H. Holdaas. (2012) Prognostic model for total mortality in patients with haemodialysis from the Assessments of Survival and Cardiovascular Events (AURORA) study. Journal of Internal Medicine 271:5, 463-471
CrossRef231
Filitsa H. Bender. (2012) Avoiding Harm in Peritoneal Dialysis Patients. Advances in Chronic Kidney Disease 19:3, 171-178
CrossRef232
Bithika Thompson, Dwight A. Towler. (2012) Arterial calcification and bone physiology: role of the bone–vascular axis. Nature Reviews Endocrinology 8:9, 529-543
CrossRef233
Rebecca Rudominer Ascunce, Jeffrey S. Berger, Howard S. Weintraub, Arthur Schwartzbard. (2012) The Role of Statin Therapy for Primary Prevention: What is the Evidence?. Current Atherosclerosis Reports 14:2, 167-174
CrossRef234
Jai Prakash. (2012) Dyslipidemia in diabetic kidney disease. Clinical Queries: Nephrology 1:2, 115-118
CrossRef235
S. Tzur, S. Rosset, K. Skorecki, W. G. Wasser. (2012) APOL1 allelic variants are associated with lower age of dialysis initiation and thereby increased dialysis vintage in African and Hispanic Americans with non-diabetic end-stage kidney disease. Nephrology Dialysis Transplantation 27:4, 1498-1505
CrossRef236
A. Kitchlu, K. Clemens, T. Gomes, D. G. Hackam, D. N. Juurlink, M. Mamdani, M. Manno, M. J. Oliver, R. R. Quinn, R. S. Suri, R. Wald, A. T. Yan, A. X. Garg. (2012) Beta-blockers and cardiovascular outcomes in dialysis patients: a cohort study in Ontario, Canada. Nephrology Dialysis Transplantation 27:4, 1591-1598
CrossRef237
Mohit Turagam, Poonam Velagapudi. (2012) The SHARP trial: Lessons learnt; answers and more questions!. International Journal of Cardiology 156:1, e6
CrossRef238
Gunnar H. Heine, Alberto Ortiz, Ziad A. Massy, Bengt Lindholm, Andrzej Wiecek, Alberto Martínez-Castelao, Adrian Covic, David Goldsmith, Gültekin Süleymanlar, Gérard M. London, Gianfranco Parati, Rosa Sicari, Carmine Zoccali, Danilo Fliser. (2012) Monocyte subpopulations and cardiovascular risk in chronic kidney disease. Nature Reviews Nephrology 8:6, 362-369
CrossRef239
Michael S. Kostapanos, Vasilios G. Athyros, Asterios Karagiannis, Dimitri P. Mikhailidis. (2012) Therapeutic options for statin-intolerant patients. Current Medical Research and Opinion 28:3, 345-349
CrossRef240
Kjell Tullus. (2012) Dyslipidemia in children with CKD: should we treat with statins?. Pediatric Nephrology 27:3, 357-362
CrossRef241
Murray Epstein, Nosratola D. Vaziri. (2012) Statins in the management of dyslipidemia associated with chronic kidney disease. Nature Reviews Nephrology 8:4, 214-223
CrossRef242
Ashish Upadhyay, Daniel E. Weiner. (2012) Lipid-Lowering Therapy in Individuals With CKD: Lessons Learned From SHARP. American Journal of Kidney Diseases 59:2, 170-173
CrossRef243
Albert Power, Kakit Chan, Seema K. Singh, David Taube, Neill Duncan. (2012) Appraising Stroke Risk in Maintenance Hemodialysis Patients: A Large Single-Center Cohort Study. American Journal of Kidney Diseases 59:2, 249-257
CrossRef244
(2012) Journal Club. Kidney International 81:4, 334-335
CrossRef245
Alejandro de la Sierra, Eduardo Alegría, Alberto Martínez-Castelao, Carlos Morillas, Diego González-Segura. (2012) Características de los pacientes con hipertensión y síndrome metabólico atendidos por diferentes especialistas. Medicina Clínica 138:4, 145-150
CrossRef246
Ron Wald, Andrew T Yan, Jeffrey Perl, Depeng Jiang, M Sandra Donnelly, Howard Leong-Poi, Philip A McFarlane, Jordan J Weinstein, Marc B Goldstein. (2012) Regression of left ventricular mass following conversion from conventional hemodialysis to thrice weekly in-centre nocturnal hemodialysis. BMC Nephrology 13:1, 3
CrossRef247
Chien-Te Lee, Yueh-Ting Lee, Hwee-Yeong Ng, Terry Ting-Yu Chiou, Cheng-I Cheng, Chien-Chun Kuo, Chien-Hsing Wu, Po-Jui Chi, Wen-Chin Lee. (2012) Lack of modulatory effect of simvastatin on indoxyl sulfate-induced activation of cultured endothelial cells. Life Sciences 90:1-2, 47-53
CrossRef248
Manjula Kurella Tamura. Neurologic Aspects of Kidney Disease. In: Brenner and Rector's The Kidney. Elsevier, 2012:2138-2155.
CrossRef249
Jane Y. Yeun, Daniel B. Ornt, Thomas A. Depner. Hemodialysis. In: Brenner and Rector's The Kidney. Elsevier, 2012:2294-2346.
CrossRef250
Hiskias G Keizer. (2012) The “Mevalonate hypothesis”: a cholesterol-independent alternative for the etiology of atherosclerosis. Lipids in Health and Disease 11:1, 149
CrossRef251
David A. Goldfarb, Emilio D. Poggio. Etiology, Pathogenesis, and Management of Renal Failure. In: Campbell-Walsh Urology. Elsevier, 2012:1193-1225.e6.
CrossRef252
Jose JG De Lima, Luis Henrique W Gowdak, Flavio J de Paula. (2012) Diagnosis and treatment of coronary artery disease in hemodialysis patients evaluated for transplant. Transplantation Research 1:1, 3
CrossRef253
Iñaki Lekuona Goya, Miren Morillas Bueno. (2012) Tratamiento de las dislipemias en situaciones especiales. Revista Española de Cardiología Suplementos 12, 26-32
CrossRef254
Yongxia Wu, Yan Wang, Chuankai An, Zhe Dong, Hui Liu, Yun Zhang, Mingxiang Zhang, Fengshuang An. (2012) Effects of Rosuvastatin and Atorvastatin on Renal Function. Circulation Journal 76:5, 1259-1266
CrossRef255
Eugene O. Apostolov, Alexei G. Basnakian, Ercan Ok, Sudhir V. Shah. (2012) Carbamylated Low-Density Lipoprotein: Nontraditional Risk Factor for Cardiovascular Events in Patients With Chronic Kidney Disease. Journal of Renal Nutrition 22:1, 134-138
CrossRef256
Joshua A. Samuels, Donald A. Molony. (2012) Randomized Controlled Trials in Nephrology: State of the Evidence and Critiquing the Evidence. Advances in Chronic Kidney Disease 19:1, 40-46
CrossRef257
James B. Wetmore, Jonathan D. Mahnken, Sally K. Rigler, Edward F. Ellerbeck, Purna Mukhopadhyay, Qingjiang Hou, Theresa I. Shireman. (2012) Association of Race with Cumulative Exposure to Statins in Dialysis. American Journal of Nephrology 36:1, 90-96
CrossRef258
Tetsuo Shoji, Takaaki Abe, Hiroshi Matsuo, Genshi Egusa, Yoshimitsu Yamasaki, Naoki Kashihara, Kohji Shirai, Atsunori Kashiwagi. (2012) Chronic Kidney Disease, Dyslipidemia, and Atherosclerosis. Journal of Atherosclerosis and Thrombosis 19:4, 299-315
CrossRef259
Peter A. McCullough. Interface Between Renal Disease and Cardiovascular Illness. In: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. Elsevier, 2012:1934-1948.
CrossRef260
Anuja Pradip Shah, Rajnish Mehrotra. Cardiovascular disease in chronic kidney disease. In: Nephrology Secrets. Elsevier, 2012:156-159.
CrossRef261
David C. Wheeler, Richard Haynes, Martin J. Landray, Colin Baigent. Cardiovascular Aspects of Kidney Disease. In: Brenner and Rector's The Kidney. Elsevier, 2012:2059-2080.
CrossRef262
Damian G. Fogarty, Maarten W. Taal. A Stepped Care Approach to the Management of Chronic Kidney Disease. In: Brenner and Rector's The Kidney. Elsevier, 2012:2205-2239.
CrossRef263
Shigeru Otsubo, Yasuko Yabuki, Miwa Ishihara, Masayo Takasaki, Syuitsu Ueda, Hisayuki Sugimoto, Yuriko Otsubo, Kosaku Nitta. (2012) Effect of cilostazol on lipid profile in hemodialysis patients. Nihon Toseki Igakkai Zasshi 45:7, 567-570
CrossRef264
Yuri Tanaka, Nobuhiko Joki, Hiroki Hase, Masaki Iwasaki, Masato Ikeda, Ryoichi Ando, Toshio Shinoda, Daijo Inaguma, Toshifumi Sakaguchi, Yasuhiro Komatsu, Fumihiko Koiwa, Toshihiko Yamaka, Takashi Shigematsu. (2012) Effect of erythropoietin-stimulating agent on uremic inflammation. Journal of Inflammation 9:1, 17
CrossRef265
Luis Rodríguez Padial, Francisco Ridocci Soriano. (2012) Eficacia bioquímica y beneficio clínico de la doble inhibición con ezetimiba y simvastatina. Revista Española de Cardiología Suplementos 12, 2-7
CrossRef266
Chun Soo Lim. (2012) Medical therapy in patients with chronic kidney disease. Journal of the Korean Medical Association 55:4, 381
CrossRef267
Khurram Nasir, Leslee J. Shaw, Matthew J. Budoff, Paul M. Ridker, Jessica M. Peña. (2012) Coronary Artery Calcium Scanning Should be Used for Primary Prevention. JACC: Cardiovascular Imaging 5:1, 111-118
CrossRef268
Yoshiki Nishizawa, Hidenori Koyama, Masaaki Inaba. (2012) AGEs and Cardiovascular Diseases in Patients With End-Stage Renal Diseases. Journal of Renal Nutrition 22:1, 128-133
CrossRef269
M. Vircoulon, C. Combe. (2012) Conséquences cardiaques de l’insuffisance rénale chronique. EMC - Néphrologie 9:1, 1-14
CrossRef270
Michael P. Delaney, Christopher P. Price, Edmund J. Lamb. Kidney Disease. In: Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Elsevier, 2012:1523-1607.
CrossRef271
Chi-yuan Hsu. Epidemiology of Kidney Disease. In: Brenner and Rector's The Kidney. Elsevier, 2012:728-741.
CrossRef272
P.P. Toth. (2012) The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Yearbook of Endocrinology 2012, 68-71
CrossRef273
Paul M Ridker, Peter Libby. Risk Markers for Atherothrombotic Disease. In: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. Elsevier, 2012:914-934.
CrossRef274
Jacques Genest, Peter Libby. Lipoprotein Disorders and Cardiovascular Disease. In: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. Elsevier, 2012:975-995.
CrossRef275
Andrew A. House. (2012) Cardio-Renal Syndrome Type 4: Epidemiology, Pathophysiology and Treatment. Seminars in Nephrology 32:1, 40-48
CrossRef276
Alberto Cordero, Iñaki Lekuona, Enrique Galve, Pilar Mazón. (2012) Novedades en hipertensión arterial y diabetes mellitus. Revista Española de Cardiología 65, 12-23
CrossRef277
Csaba P. Kovesdy, Kamyar Kalantar-Zadeh. (2012) Observational Studies Versus Randomized Controlled Trials: Avenues to Causal Inference in Nephrology. Advances in Chronic Kidney Disease 19:1, 11-18
CrossRef278
Anabela Malho Guedes, Pedro Leão Neves. (2012) Statins for Renal Patients: A Fiddler on the Roof?. International Journal of Nephrology 2012, 1-7
CrossRef279
Shusuke Yagi, Ken-ichi Aihara, Yasumasa Ikeda, Masashi Akaike, Masataka Sata, Toshio Matsumoto. (2012) Effects of Statins on Cardiorenal Syndrome. International Journal of Vascular Medicine 2012, 1-7
CrossRef280
Andrew S Levey, Josef Coresh. (2012) Chronic kidney disease. The Lancet 379:9811, 165-180
CrossRef281
Elizabeth Gorevski, Boyang Bian, Christina M.L. Kelton, Jill E. Martin Boone, Jeff J. Guo. (2012) Evidence-Based Prediction of Statin Use with Lipid-Panel Data from the National Health and Nutrition Examination Survey. Value in Health 15:1, 32-38
CrossRef282
A. S. Wierzbicki. (2011) The ezetimibe Jonah: the trials and tribulations of an unlucky drug. International Journal of Clinical Practice 65:12, 1207-1208
CrossRef283
J. E. Lee, K.-H. Oh, K. H. Choi, S. B. Kim, Y.-S. Kim, J.-Y. Do, Y.-L. Kim, D. J. Kim. (2011) Statin therapy is associated with improved survival in incident peritoneal dialysis patients: propensity-matched comparison. Nephrology Dialysis Transplantation 26:12, 4090-4094
CrossRef284
Željko Reiner, Alberico L. Catapano, Guy De Backer, Ian Graham, Marja-Riitta Taskinen, Olov Wiklund, Stefan Agewall, Eduardo Alegría, M. John Chapman, Paul Durrington, Serap Erdine, Julian Halcox, Richard Hobbs, John Kjekshus, Pasquale Perrone Filardi, Gabriele Riccardi, Robert F. Storey, David Wood. (2011) Guía de la ESC/EAS sobre el manejo de las dislipemias. Revista Española de Cardiología 64:12, 1168.e1-1168.e60
CrossRef285
Emma Burnhope, Darren Green, Philip A Kalra, Paul R Kalra. (2011) Current developments in lipid-lowering therapy for the patient with chronic kidney disease. Clinical Lipidology 6:6, 693-702
CrossRef286
Kiyoshi Hibi, Takeshi Kimura, Kazuo Kimura, Takeshi Morimoto, Takafumi Hiro, Katsumi Miyauchi, Yoshihisa Nakagawa, Masakazu Yamagishi, Yukio Ozaki, Satoshi Saito, Tetsu Yamaguchi, Hiroyuki Daida, Masunori Matsuzaki. (2011) Clinically evident polyvascular disease and regression of coronary atherosclerosis after intensive statin therapy in patients with acute coronary syndrome: Serial intravascular ultrasound from the Japanese assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS) trial. Atherosclerosis 219:2, 743-749
CrossRef287
Michael M. Hoffmann, Winfried März, Bernd Genser, Christiane Drechsler, Christoph Wanner. (2011) Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and cardiovascular risk and efficacy of atorvastatin among subjects with diabetes on dialysis: The 4D study. Atherosclerosis 219:2, 659-662
CrossRef288
C.-C. Wu, H.-H. Liou, P.-F. Su, M.-Y. Chang, H.-H. Wang, M.-J. Chen, S.-Y. Hung. (2011) Abdominal obesity is the most significant metabolic syndrome component predictive of cardiovascular events in chronic hemodialysis patients. Nephrology Dialysis Transplantation 26:11, 3689-3695
CrossRef289
Jeffrey S. Berns. (2011) A SHARP Study, But With Blunted Conclusions. Seminars in Dialysis 24:6, 684-685
CrossRef290
Tetsu Miyamoto, Juan J. Carrero, Peter Stenvinkel. (2011) Inflammation as a risk factor and target for therapy in chronic kidney disease. Current Opinion in Nephrology and Hypertension 20:6, 662-668
CrossRef291
B. L. Ng, M. Anpalahan. (2011) Management of chronic kidney disease in the elderly. Internal Medicine Journal 41:11, 761-768
CrossRef292
Alberto Ortiz, Ziad A. Massy, Danilo Fliser, Bengt Lindholm, Andrzej Wiecek, Alberto Martínez-Castelao, Adrian Covic, David Goldsmith, Gültekin Süleymanlar, Gérard M. London, Carmine Zoccali. (2011) Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis. Nature Reviews Nephrology 8:3, 141-150
CrossRef293
Eugene P. Rhee, Ravi Thadhani. (2011) New insights into uremia-induced alterations in metabolic pathways. Current Opinion in Nephrology and Hypertension 20:6, 593-598
CrossRef294
Kalani L. Raphael, Alfred K. Cheung. (2011) Implications of the Frequent Hemodialysis Network-Daily Trial. Seminars in Dialysis 24:6, 621-628
CrossRef295
S. H. Han, E. W. Kang, S.-J. Yoon, H. S. Yoon, H. C. Lee, T. H. Yoo, K. H. Choi, D.-S. Han, S.-W. Kang. (2011) Combined vascular effects of HMG-CoA reductase inhibitor and angiotensin receptor blocker in non-diabetic patients undergoing peritoneal dialysis. Nephrology Dialysis Transplantation 26:11, 3722-3728
CrossRef296
D. O. Dahle, G. Mjoen, B. Oqvist, H. Scharnagl, G. Weihrauch, T. Grammer, W. Marz, S. Abedini, G. E. Norby, I. Holme, B. Fellstrom, A. Jardine, H. Holdaas. (2011) Inflammation-associated graft loss in renal transplant recipients. Nephrology Dialysis Transplantation 26:11, 3756-3761
CrossRef297
Kevin E Chan, T Alp Ikizler, Jorge L Gamboa, Chang Yu, Raymond M Hakim, Nancy J Brown. (2011) Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients. Kidney International 80:9, 978-985
CrossRef298
Peter P Toth, Thomas D Dayspring. (2011) Drug safety evaluation of rosuvastatin. Expert Opinion on Drug Safety 10:6, 969-986
CrossRef299
Stephen J Nicholls, Kiyoko Uno, Yu Kataoka. (2011) Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk. Expert Review of Cardiovascular Therapy 9:11, 1383-1390
CrossRef300
Brett W. Stephens, Aleksandra M. De Golovine, Risheng Xu, Donald A. Molony. (2011) How the latest evidence from clinical research informs patient care. Dialysis & Transplantation 40:10, 467-470
CrossRef301
(2011) Journal Club. Kidney International 80:7, 690-691
CrossRef302
M. Chmielewski, M. Verduijn, C. Drechsler, B. Lindholm, P. Stenvinkel, B. Rutkowski, E. W. Boeschoten, R. T. Krediet, F. W. Dekker. (2011) Low cholesterol in dialysis patients--causal factor for mortality or an effect of confounding?. Nephrology Dialysis Transplantation 26:10, 3325-3331
CrossRef303
Juliana C.N. Chan, Siew Pheng Chan, Chaicharn Deerochanawong, Ruby T. Go, Kok-Onn Lee, Ronald Ching-Wan Ma, Chang-Yu Pan, Wayne H-H. Sheu, Philip Barter. (2011) Diabetic dyslipidaemia in Asian populations in the Western Pacific Region: What we know and don’t know. Diabetes Research and Clinical Practice 94:1, 1-13
CrossRef304
Joseph Menzin, Lisa M. Lines, Daniel E. Weiner, Peter J. Neumann, Christine Nichols, Lauren Rodriguez, Irene Agodoa, Tracy Mayne. (2011) A Review of the Costs and Cost Effectiveness of Interventions in Chronic Kidney Disease. PharmacoEconomics 29:10, 839-861
CrossRef305
Jaime García de Tena, Laura Abejón, David Bernal, Estefanía Águila, Manuel Rodríguez-Zapata. (2011) Benefits of lowering cholesterol in chronic kidney disease. The Lancet 378:9800, 1376
CrossRef306
Jeppe Hagstrup Christensen, Erik Berg Schmidt, My Svensson. (2011) n-3 polyunsaturated fatty acids, lipids and lipoproteins in end-stage renal disease. Clinical Lipidology 6:5, 563-576
CrossRef307
Suetonia C. Palmer, Giovanni F. M. Strippoli. (2011) Cardiovascular diseases: Lipid-lowering in CKD—at the SHARP end of the evidence?. Nature Reviews Nephrology 7:11, 609-611
CrossRef308
Charles A Herzog, Richard W Asinger, Alan K Berger, David M Charytan, Javier Díez, Robert G Hart, Kai-Uwe Eckardt, Bertram L Kasiske, Peter A McCullough, Rod S Passman, Stephanie S DeLoach, Patrick H Pun, Eberhard Ritz. (2011) Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney International 80:6, 572-586
CrossRef309
Sunil V. Badve, Matthew A. Roberts, Carmel M. Hawley, Alan Cass, Amit X. Garg, Henry Krum, Andrew Tonkin, Vlado Perkovic. (2011) Effects of Beta-Adrenergic Antagonists in Patients With Chronic Kidney Disease. Journal of the American College of Cardiology 58:11, 1152-1161
CrossRef310
Tara I. Chang, Glenn M. Chertow. (2011) Chronic Kidney Disease and Cardiovascular Therapeutics. Journal of the American College of Cardiology 58:11, 1162-1164
CrossRef311
G.B. John Mancini, Steven Baker, Jean Bergeron, David Fitchett, Jiri Frohlich, Jacques Genest, Milan Gupta, Robert A. Hegele, Dominic Ng, Janet Pope. (2011) Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Proceedings of a Canadian Working Group Consensus Conference. Canadian Journal of Cardiology 27:5, 635-662
CrossRef312
Keith R. Solomon, Michael R. Freeman. (2011) The Complex Interplay Between Cholesterol and Prostate Malignancy. Urologic Clinics of North America 38:3, 243-259
CrossRef313
Fabio Fabbian, Alfredo Giorgi, Marco Pala, Ruana Tiseo, Roberto Manfredini, Francesco Portaluppi. (2011) Evidence-based statin prescription for cardiovascular protection in renal impairment. Clinical and Experimental Nephrology 15:4, 456-463
CrossRef314
S. Yamamoto, Y. Zuo, J. Ma, P. G. Yancey, T. E. Hunley, M. Motojima, A. B. Fogo, M. F. Linton, S. Fazio, I. Ichikawa, V. Kon. (2011) Oral activated charcoal adsorbent (AST-120) ameliorates extent and instability of atherosclerosis accelerated by kidney disease in apolipoprotein E-deficient mice. Nephrology Dialysis Transplantation 26:8, 2491-2497
CrossRef315
P.-O. Attman, O. Samuelsson, P. Alaupovic. (2011) The effect of decreasing renal function on lipoprotein profiles. Nephrology Dialysis Transplantation 26:8, 2572-2575
CrossRef316
T. Breidthardt, S. Kalbermatter, T. Socrates, M. Noveanu, T. Klima, A. Mebazaa, C. Mueller, D. Kiss. (2011) Increasing B-type natriuretic peptide levels predict mortality in unselected haemodialysis patients. European Journal of Heart Failure 13:8, 860-867
CrossRef317
, , Z. Reiner, A. L. Catapano, G. De Backer, I. Graham, M.-R. Taskinen, O. Wiklund, S. Agewall, E. Alegria, M. J. Chapman, P. Durrington, S. Erdine, J. Halcox, R. Hobbs, J. Kjekshus, P. P. Filardi, G. Riccardi, R. F. Storey, D. Wood, , J. Bax, A. Vahanian, A. Auricchio, H. Baumgartner, C. Ceconi, V. Dean, C. Deaton, R. Fagard, G. Filippatos, C. Funck-Brentano, D. Hasdai, R. Hobbs, A. Hoes, P. Kearney, J. Knuuti, P. Kolh, T. McDonagh, C. Moulin, D. Poldermans, B. A. Popescu, Z. Reiner, U. Sechtem, P. A. Sirnes, M. Tendera, A. Torbicki, P. Vardas, P. Widimsky, S. Windecker, D. Reviewers:, C. Funck-Brentano, D. Poldermans, G. Berkenboom, J. De Graaf, O. Descamps, N. Gotcheva, K. Griffith, G. F. Guida, S. Gulec, Y. Henkin, K. Huber, Y. A. Kesaniemi, J. Lekakis, A. J. Manolis, P. Marques-Vidal, L. Masana, J. McMurray, M. Mendes, Z. Pagava, T. Pedersen, E. Prescott, Q. Rato, G. Rosano, S. Sans, A. Stalenhoef, L. Tokgozoglu, M. Viigimaa, M. E. Wittekoek, J. L. Zamorano. (2011) ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal 32:14, 1769-1818
CrossRef318
Matthew A. Roberts, Kevan R. Polkinghorne, Stephen P. McDonald, Francesco L. Ierino. (2011) Secular Trends in Cardiovascular Mortality Rates of Patients Receiving Dialysis Compared With the General Population. American Journal of Kidney Diseases 58:1, 64-72
CrossRef319
Friso L.H. Muntinghe, Stefan Vegter, Marion Verduijn, Elisabeth W. Boeschoten, Friedo W. Dekker, Gerjan Navis, Maarten Postma. (2011) Using a genetic, observational study as a strategy to estimate the potential cost-effectiveness of pharmacological CCR5 blockade in dialysis patients. Pharmacogenetics and Genomics 21:7, 417-425
CrossRef320
David C. Mendelssohn, Braden J. Manns. (2011) A Proposal for Improving Evidence Generation in Nephrology. American Journal of Kidney Diseases 58:1, 13-18
CrossRef321
S. Agewall. (2011) The large clinical statin trials. International Journal of Cardiology 150:1, 108-111
CrossRef322
Luís Mendes Pedro. (2011) Prevenção secundária com estatinas na patologia arterial periférica aterosclerótica. Revista Portuguesa de Cardiologia 30:7-8, 665-673
CrossRef323
Mark J. Sarnak, Robert N. Foley. (2011) Cardiovascular Mortality in the General Population Versus Dialysis: A Glass Half Full or Empty?. American Journal of Kidney Diseases 58:1, 4-6
CrossRef324
Mehmet KOC, Cengiz DOGAN, Turgay ARINSOY, Zeki TONBUL, Deniz AYLI, Mustafa CIRIT, Mehmet Sukru SEVER, Mehmet Emin YILMAZ, Abdulkadir UNSAL, Gultekin SULEYMANLAR, Ercan OK, Ali BASCI, Alaatin YILDIZ. (2011) Statin use is associated with lower inflammation and erythropoietin responsiveness index in hemodialysis patients. Hemodialysis International 15:3, 366-373
CrossRef325
Charlie Tomson, Pippa Bailey. (2011) Management of chronic kidney disease. Medicine 39:7, 407-413
CrossRef326
T. Miyamoto, A. Rashid Qureshi, T. Yamamoto, A. Nakashima, B. Lindholm, P. Stenvinkel, A. Alvestrand, J. Axelsson. (2011) Postprandial metabolic response to a fat- and carbohydrate-rich meal in patients with chronic kidney disease. Nephrology Dialysis Transplantation 26:7, 2231-2237
CrossRef327
Patrick Mark, Alan Jardine. (2011) Cardiovascular complications of chronic renal disease. Medicine 39:7, 421-424
CrossRef328
Luís Mendes Pedro. (2011) The role of statins in atherosclerotic peripheral arterial disease. Revista Portuguesa de Cardiologia (English Edition) 30:7-8, 665-673
CrossRef329
Alberico L. Catapano, Željko Reiner, Guy De Backer, Ian Graham, Marja-Riitta Taskinen, Olov Wiklund, Stefan Agewall, Eduardo Alegria, M. John Chapman, Paul Durrington, Serap Erdine, Julian Halcox, Richard Hobbs, John Kjekshus, Pasquale Perrone Filardi, Gabriele Riccardi, Robert F. Storey, David Wood. (2011) ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis 217, 1-44
CrossRef330
DJ Blom. (2011) Secondary dyslipidaemia. South African Family Practice 53:4, 317-323
CrossRef331
Alberico L. Catapano, Željko Reiner, Guy De Backer, Ian Graham, Marja-Riitta Taskinen, Olov Wiklund, Stefan Agewall, Eduardo Alegria, M. John Chapman, Paul Durrington, Serap Erdine, Julian Halcox, Richard Hobbs, John Kjekshus, Pasquale Perrone Filardi, Gabriele Riccardi, Robert F. Storey, David Wood. (2011) ESC/EAS Guidelines for the management of dyslipidaemias. Atherosclerosis 217:1, 3-46
CrossRef332
Adeera Levin, Paul E. Stevens. (2011) Early detection of CKD: the benefits, limitations and effects on prognosis. Nature Reviews Nephrology 7:8, 446-457
CrossRef333
Darren Green, Paul R. Roberts, David I. New, Philip A. Kalra. (2011) Sudden Cardiac Death in Hemodialysis Patients: An In-Depth Review. American Journal of Kidney Diseases 57:6, 921-929
CrossRef334
Debasish Banerjee, Alejandro Recio-Mayoral, Nihil Chitalia, Juan-Carlos Kaski. (2011) Insulin Resistance, Inflammation, and Vascular Disease in Nondiabetic Predialysis Chronic Kidney Disease Patients. Clinical Cardiology 34:6, 360-365
CrossRef335
Angela Yee-Moon WANG. (2011) Cardiovascular risk in diabetic end-stage renal disease patients. Journal of Diabetes 3:2, 119-131
CrossRef336
Kitty J Jager, Bengt Lindholm, David Goldsmith, Danilo Fliser, Andrzej Wiecek, Gultekin Suleymanlar, Alberto Ortiz, Ziad Massy, Alberto Martinez-Castelao, Rajiv Agarwal, Peter J Blankestijn, Adrian Covic, Gerard London, Carmine Zoccali, Friedo W Dekker. (2011) Cardiovascular and non-cardiovascular mortality in dialysis patients: where is the link?. Kidney International Supplements 1:1, 21-23
CrossRef337
Werner Ribitsch, Alexander R Rosenkranz. (2011) Prehypertension and prechronic kidney disease: fact or fiction?. Expert Review of Cardiovascular Therapy 9:6, 651-653
CrossRef338
Kathryn K Stevens, Alan G Jardine. (2011) SHARP: a stab in the right direction in chronic kidney disease. The Lancet 377:9784, 2153-2154
CrossRef339
Colin Baigent, Martin J Landray, Christina Reith, Jonathan Emberson, David C Wheeler, Charles Tomson, Christoph Wanner, Vera Krane, Alan Cass, Jonathan Craig, Bruce Neal, Lixin Jiang, Lai Seong Hooi, Adeera Levin, Lawrence Agodoa, Mike Gaziano, Bertram Kasiske, Robert Walker, Ziad A Massy, Bo Feldt-Rasmussen, Udom Krairittichai, Vuddidhej Ophascharoensuk, Bengt Fellström, Hallvard Holdaas, Vladimir Tesar, Andrzej Wiecek, Diederick Grobbee, Dick de Zeeuw, Carola Grönhagen-Riska, Tanaji Dasgupta, David Lewis, William Herrington, Marion Mafham, William Majoni, Karl Wallendszus, Richard Grimm, Terje Pedersen, Jonathan Tobert, Jane Armitage, Alex Baxter, Christopher Bray, Yiping Chen, Zhengming Chen, Michael Hill, Carol Knott, Sarah Parish, David Simpson, Peter Sleight, Alan Young, Rory Collins. (2011) The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. The Lancet 377:9784, 2181-2192
CrossRef340
Vera Krane, Christoph Wanner. (2011) Statins, inflammation and kidney disease. Nature Reviews Nephrology 7:7, 385-397
CrossRef341
Kamyar Kalantar-Zadeh, Noël J. Cano, Klemens Budde, Charles Chazot, Csaba P. Kovesdy, Robert H. Mak, Rajnish Mehrotra, Dominic S. Raj, Ashwini R. Sehgal, Peter Stenvinkel, T. Alp Ikizler. (2011) Diets and enteral supplements for improving outcomes in chronic kidney disease. Nature Reviews Nephrology 7:7, 369-384
CrossRef342
Thomas D. Nolin, Vikram Arya, Daniel S. Sitar, Marc Pfister. (2011) Optimizing Drug Development and Use in Patients With Kidney Disease. The Journal of Clinical Pharmacology 51:5, 628-630
CrossRef343
Karolina Szummer, Pia Lundman, Stefan H Jacobson, Staffan Schön, Johan Lindbäck, Ulf Stenestrand, Lars Wallentin, Tomas Jernberg. (2011) Association between statin treatment and outcome in relation to renal function in survivors of myocardial infarction. Kidney International 79:9, 997-1004
CrossRef344
Robert N. Foley. (2011) A Perfect Cardiomyopathic Storm. Seminars in Dialysis 24:3, 278-279
CrossRef345
W. Kleophas. (2011) Diabetes und Dialyse. Der Diabetologe 7:3, 201-212
CrossRef346
Noémie Jourde-Chiche, Laetitia Dou, Claire Cerini, Françoise Dignat-George, Philippe Brunet. (2011) Vascular Incompetence in Dialysis Patients-Protein-Bound Uremic Toxins and Endothelial Dysfunction. Seminars in Dialysis 24:3, 327-337
CrossRef347
D. John Betteridge. (2011) Lipid control in patients with diabetes mellitus. Nature Reviews Cardiology 8:5, 278-290
CrossRef348
Bengt C Fellström. (2011) Cardioprotective role of statins in chronic kidney disease: do we have the answer?. Kidney International 79:9, 931-932
CrossRef349
Paolo Cravedi, Giuseppe Remuzzi, Piero Ruggenenti. (2011) Targeting the Renin Angiotensin System in Dialysis Patients. Seminars in Dialysis 24:3, 290-297
CrossRef350
John P. Middleton. (2011) Predisposition to Arrhythmias: Electrolytes, Uremic Fibrosis, Other Factors. Seminars in Dialysis 24:3, 287-289
CrossRef351
Charles A. Herzog. (2011) Is There Something Special About Coronary Artery Disease in Dialysis Patients?. Seminars in Dialysis 24:3, 280-282
CrossRef352
J.-K. Lee, H.-H. Lin, C.-T. Tsai, J.-J. Chen, C.-C. Kuo, Y.-C. Lien, J.-W. Lin, J.-W. Huang, S.-W. Hwang, J.-J. Hwang, C.-D. Tseng, F.-T. Chiang, J.-J. Chen, C.-K. Wu. (2011) Differential association of proinflammatory cytokines with left ventricular diastolic dysfunction in subjects with and without continuous ambulatory peritoneal dialysis. Nutrition, Metabolism and Cardiovascular Diseases
CrossRef353
Ariel Brautbar, Christie M. Ballantyne. (2011) Pharmacological strategies for lowering LDL cholesterol: statins and beyond. Nature Reviews Cardiology 8:5, 253-265
CrossRef354
A. L. M. de Francisco. (2011) Reply. Nephrology Dialysis Transplantation 26:4, 1443-1444
CrossRef355
Maurizio Postorino, Carmen Marino, Giovanni Tripepi, Carmine Zoccali. (2011) Abdominal obesity modifies the risk of hypertriglyceridemia for all-cause and cardiovascular mortality in hemodialysis patients. Kidney International 79:7, 765-772
CrossRef356
J. J. G. De Lima, L. H. W. Gowdak, F. J. de Paula, R. L. Arantes, L. A. M. Cesar, J. A. F. Ramires, E. M. Krieger. (2011) Unexplained sudden death in patients on the waiting list for renal transplantation. Nephrology Dialysis Transplantation 26:4, 1392-1396
CrossRef357
Ali Olyaei, Edgar V. Lerma. (2011) Three strikes and statins out: A case against use of statins in dialysis patients for primary prevention. Dialysis & Transplantation 40:4, 148-151
CrossRef358
Vimal Ramjee, Terry A Jacobson. (2011) Intensifying statin therapy to maximize cardiovascular risk reduction: is 50 the new 70? Goals are getting old. Clinical Lipidology 6:2, 131-136
CrossRef359
Harry R. Davis, Robert S. Lowe, David R. Neff. (2011) Effects of ezetimibe on atherosclerosis in preclinical models. Atherosclerosis 215:2, 266-278
CrossRef360
Edward L. Korn, Boris Freidlin. (2011) Inefficacy Interim Monitoring Procedures in Randomized Clinical Trials: The Need to Report. The American Journal of Bioethics 11:3, 2-10
CrossRef361
M. Ruiz-Bailén, J. Pérez-Valenzuela, A. Ferrezuelo-Mata, R.J. Obra-Cuadra. (2011) Efecto de la administración de las estatinas en la patología crítica no cardiológica. Medicina Intensiva 35:2, 107-116
CrossRef362
Sankar D Navaneethan, Jörgen Hegbrant, Giovanni FM Strippoli. (2011) Role of statins in preventing adverse cardiovascular outcomes in patients with chronic kidney disease. Current Opinion in Nephrology and Hypertension 20:2, 146-152
CrossRef363
Lynda Szczech. (2011) CKD and CVD: No Need for a Turf War. Nephrology Times 4:3, 4-5
CrossRef364
Christiaan L. Meuwese, Peter Stenvinkel, Friedo W. Dekker, Juan J. Carrero. (2011) Monitoring of inflammation in patients on dialysis: forewarned is forearmed. Nature Reviews Nephrology 7:3, 166-176
CrossRef365
Kosmas I. Paraskevas, Sotirios A. Koupidis, Alexandros A. Tzovaras, Achilleas Nikolaou, Dimitri P. Mikhailidis. (2011) Screening for peripheral artery disease in dialysis patients: an opportunity for early disease detection and timely initiation of appropriate therapeutic measures. International Urology and Nephrology 43:1, 143-145
CrossRef366
Pauline A. Swift, Peter A. Andrews. (2011) Medications to Reduce Cardiovascular Risk After Kidney Transplantation. Transplantation 91:5, 492-493
CrossRef367
MATTHEW A ROBERTS, ADAM J HEDLEY, FRANCESCO L IERINO. (2011) Understanding cardiac biomarkers in end-stage kidney disease: Frequently asked questions and the promise of clinical application. Nephrology 16:3, 251-260
CrossRef368
Pamela M. Katz, Aurora A. Mendelsohn, Shaun G. Goodman, Anatoly Langer, Hwee Teoh, Lawrence A. Leiter. (2011) Use of a Treatment Optimization Algorithm Involving Statin-Ezetimibe Combination Aids in Achievement of Guideline-Based Low-Density Lipoprotein Targets in Patients With Dyslipidemia at High Vascular Risk Guideline-Based Undertaking to Improve Dyslipidemia Management in Canada (GUIDANC). Canadian Journal of Cardiology 27:2, 138-145
CrossRef369
Sankar D Navaneethan, Suetonia C Palmer, Mariacristina Vecchio, Jonathan C Craig, Grahame J Elder, Giovanni FM Strippoli, Sankar D Navaneethan. Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2011.
CrossRef370
Abhishek Deshmukh, Jawahar L. Mehta. (2011) Statins and Renal Disease: Friend or Foe?. Current Atherosclerosis Reports 13:1, 57-63
CrossRef371
My Svensson, Kaj Anker Jørgensen, Jeppe Hagstrup Christensen. (2011) Omega-3 Polyunsaturated Fatty Acids and Clinical Trials. American Journal of Kidney Diseases 57:2, 352
CrossRef372
Joel A. Lardizabal, Prakash Deedwania. (2011) Lipid-Lowering Therapy with Statins for the Primary and Secondary Prevention of Cardiovascular Disease. Cardiology Clinics 29:1, 87-103
CrossRef373
Hemmelgarn , Brenda R. , Moist , Louise M. , Lok , Charmaine E. , Tonelli , Marcello , Manns , Braden J. , Holden , Rachel M. , LeBlanc , Martine , Faris , Peter , Barre , Paul , Zhang , Jianguo , Scott-Douglas , Nairne , . (2011) Prevention of Dialysis Catheter Malfunction with Recombinant Tissue Plasminogen Activator. New England Journal of Medicine 364:4, 303-312
Free Full Text374
Jorge E. Echeverri, Rinaldo Bellomo. Renal dysfunction in the coronary care unit. In: Coronary Care Manual. Elsevier, 2011:610-618.
CrossRef375
(2011) Nihon Toseki Igakkai Zasshi 44:5, 347-352
CrossRef376
Insuffisance Rénale et Vaisseaux. In: Traité de médecine vasculaire.. Elsevier, 2011:553-579.
CrossRef377
M. Ruiz-Bailén, J. Pérez-Valenzuela, A. Ferrezuelo-Mata, R.J. Obra-Cuadra. (2011) Effect of the administration of statins in non-cardiac critical disease. Medicina Intensiva (English Edition) 35:2, 107-116
CrossRef378
Vivencio Barrios Alonso, Carlos Escobar Cervantes. (2011) Valor de la dislipemia en el conjunto de los factores de riesgo cardiovascular. Revista Española de Cardiología Suplementos 11, 29-35
CrossRef379
(2011) Nihon Toseki Igakkai Zasshi 44:5, 353-357
CrossRef380
Elizabeth P Tolmie, Eleanor M Dinnett, Elizabeth S Ronald, Allan Gaw, . (2011) Clinical Trials: Minimising source data queries to streamline endpoint adjudication in a large multi-national trial. Trials 12:1, 112
CrossRef381
George A. Kaysen. (2011) New Insights Into Lipid Metabolism in Chronic Kidney Disease. Journal of Renal Nutrition 21:1, 120-123
CrossRef382
Stephen Holt, David Goldsmith. (2011) Renal Association Clinical Practice Guideline on Cardiovascular Disease in CKD. Nephron Clinical Practice 118:s1, c125-c144
CrossRef383
Valentina Kon, MacRae F. Linton, Sergio Fazio. (2011) Atherosclerosis in chronic kidney disease: the role of macrophages. Nature Reviews Nephrology 7:1, 45-54
CrossRef384
Denis Fouque, William E. Mitch. Dietary Approaches to Kidney Diseases. In: Brenner and Rector's The Kidney. Elsevier, 2011:2170-2204.
CrossRef385
M. Alberton, P. Wu, E. Druyts, M. Briel, E. J. Mills. (2011) Adverse events associated with individual statin treatments for cardiovascular disease: an indirect comparison meta-analysis. QJM 105:2, 145
CrossRef386
Rigas G. Kalaitzidis, Moses S. Elisaf. (2011) The Role of Statins in Chronic Kidney Disease. American Journal of Nephrology 34:3, 195-202
CrossRef387
Jeff S Coombes, Robert G Fassett. (2011) Antioxidant therapy in hemodialysis patients: a systematic review. Kidney International 81:3, 233
CrossRef388
Carolyn L van Eps, Leanne Jeffriess, Brian Haluska, Carmel M Hawley, Jeffrey Coombes, Aya Matsumoto, Janine K Jeffries, David W Johnson, Scott B Campbell, Nicole M Isbel, David W Mudge, Thomas Marwick. (2011) Cardiac and vascular structure and function parameters do not improve with alternate nightly home hemodialysis: An interventional cohort study. BMC Nephrology 12:1, 51
CrossRef389
Patricia Wilson, Katie Brandewie, Deepa Taneja, Liliana Schaefer, Bonnie Mitchell, Lisa R. Tannock, Joel Thompson. (2011) Renal Accumulation of Biglycan and Lipid Retention Accelerates Diabetic Nephropathy. American Journal Of Pathology 179:3, 1179
CrossRef390
Masahiro Natsuaki, Yutaka Furukawa, Takeshi Morimoto, Yoshihisa Nakagawa, Masaharu Akao, Koh Ono, Tetsuo Shioi, Satoshi Shizuta, Ryuzo Sakata, Hitoshi Okabayashi, Noboru Nishiwaki, Tatsuhiko Komiya, Satoru Suwa, Takeshi Kimura. (2011) Impact of Diabetes on Cardiovascular Outcomes in Hemodialysis Patients Undergoing Coronary Revascularization. Circulation Journal 75:7, 1616-1625
CrossRef391
Tetsuo Shoji. (2011) Nihon Toseki Igakkai Zasshi 44:12, 1136-1138
CrossRef392
Mark S. MacGregor, Maarten W. Taal. (2011) Renal Association Clinical Practice Guideline on Detection, Monitoring and Management of Patients with CKD. Nephron Clinical Practice 118:s1, c71-c100
CrossRef393
Timothy W. Meyer, Thomas H. Hostetter. The Pathophysiology of Uremia. In: Brenner and Rector's The Kidney. Elsevier, 2011:2000-2020.
CrossRef394
Raymond Oliva, Tamar Polonsky, George L. Bakris. Advanced Risk Assessment in Patients with Kidney and Inflammatory Diseases. In: Preventive Cardiology: Companion to Braunwald's Heart Disease. Elsevier, 2011:64-68.
CrossRef395
Elvira O. Gosmanova, Ngoc-Anh Le. (2011) Cardiovascular Complications in CKD Patients: Role of Oxidative Stress. Cardiology Research and Practice 2011, 1-8
CrossRef396
Panagiotis Pateinakis, Aikaterini Papagianni. (2011) Cardiorenal Syndrome Type 4—Cardiovascular Disease in Patients with Chronic Kidney Disease: Epidemiology, Pathogenesis, and Management. International Journal of Nephrology 2011, 1-8
CrossRef397
Andrew A. House, Mikko Haapio, Johan Lassus, Rinaldo Bellomo, Claudio Ronco. (2011) Pharmacological Management of Cardiorenal Syndromes. International Journal of Nephrology 2011, 1-8
CrossRef398
José Álvaro Bonet Plá, Victoria Gosalbes Soler, Armando Berioz Heiland. (2010) Alteraciones metabólicas en la enfermedad renal crónica. FMC - Formación Médica Continuada en Atención Primaria 17:10, 647-655
CrossRef399
Tae Kaneda, Shuichi Tsuruoka, Akio Fujimura. (2010) Statins inhibited erythropoietin-induced proliferation of rat vascular smooth muscle cells. European Journal of Pharmacology 649:1-3, 38-43
CrossRef400
Kosmas I. Paraskevas, Ioannis Kotsikoris, Sotirios A. Koupidis, Alexandros A. Tzovaras, Dimitri P. Mikhailidis. (2010) Cardiovascular events in chronic dialysis patients: emphasizing the importance of vascular disease prevention. International Urology and Nephrology 42:4, 999-1006
CrossRef401
S. Seiler, B. Reichart, D. Roth, E. Seibert, D. Fliser, G. H. Heine. (2010) FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrology Dialysis Transplantation 25:12, 3983-3989
CrossRef402
W Charles O'Neill, Koba A Lomashvili. (2010) Recent progress in the treatment of vascular calcification. Kidney International 78:12, 1232-1239
CrossRef403
Tilman B. Drüeke, Ziad A. Massy. (2010) Atherosclerosis in CKD: differences from the general population. Nature Reviews Nephrology 6:12, 723-735
CrossRef404
Lisa M. Miller, Manish M. Sood, Amy R. Sood, Martina Reslerova, Paul Komenda, Claudio Rigatto, Joe Bueti. (2010) Cardiovascular disease in end-stage renal disease: the challenge of assessing and managing cardiac disease in dialysis patients. International Urology and Nephrology 42:4, 1007-1014
CrossRef405
A. Power, S. Moser, N. Duncan. (2010) Successful thrombolysis for acute ischaemic stroke in haemodialysis. NDT Plus 3:6, 576-578
CrossRef406
Roberto Scarpioni, Marco Ricardi, Luigi Melfa, Luciano Cristinelli. (2010) Dyslipidemia in Chronic Kidney Disease: Are Statins Still Indicated in Reduction Cardiovascular Risk in Patients on Dialysis Treatment?. Cardiovascular Therapeutics 28:6, 361-368
CrossRef407
F. Yang, D. Chou, P. Schweitzer, S. Hanon. (2010) Warfarin in haemodialysis patients with atrial fibrillation: what benefit?. Europace 12:12, 1666-1672
CrossRef408
Himmelfarb , Jonathan , Ikizler , T. Alp , . (2010) Hemodialysis. New England Journal of Medicine 363:19, 1833-1845
Full Text409
P. Stenvinkel. (2010) Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. Journal of Internal Medicine 268:5, 456-467
CrossRef410
Theodoros I. Kassimatis, Athanasios Agrafiotis. (2010) Chronic kidney disease: Implications of the AURORA and JUPITER results. Nature Reviews Nephrology 6:11, 636-637
CrossRef411
H.- Y. Chen, Y.- L. Chiu, S.- P. Hsu, M.- F. Pai, C.- F. Lai, J.- Y. Yang, Y.- S. Peng, T.- J. Tsai, K.- D. Wu. (2010) Elevated C-reactive protein level in hemodialysis patients with moderate/severe uremic pruritus: a potential mediator of high overall mortality. QJM 103:11, 837-846
CrossRef412
Richard J. Haynes, Christopher G. Winearls. (2010) Chronic kidney disease. Surgery (Oxford) 28:11, 525-529
CrossRef413
Kyle L. Dawson, Samir J. Patel, David Putney, Wadi N. Suki, A. Osama Gaber. (2010) Cardioprotective medication use after renal transplantation. Clinical Transplantation 24:6, E253-E256
CrossRef414
M. G. H. Betjes, E. E. A. de Wit, W. Weimar, N. H. R. Litjens. (2010) Circulating pro-inflammatory CD4posCD28null T cells are independently associated with cardiovascular disease in ESRD patients. Nephrology Dialysis Transplantation 25:11, 3640-3646
CrossRef415
Kamyar Kalantar-Zadeh, Eliezer Golan, Tamy Shohat, Elani Streja, Keith C. Norris, Joel D. Kopple. (2010) Survival Disparities within American and Israeli Dialysis Populations: Learning from Similarities and Distinctions across Race and Ethnicity. Seminars in Dialysis 23:6, 586-594
CrossRef416
SHARP Collaborative Group. (2010) Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. American Heart Journal 160:5, 785-794.e10
CrossRef417
Kevin E. Chan, Raymond Hakim. (2010) Association of digoxin with mortality in ESRD: Does the medical evidence still apply when the patient is on dialysis?. Dialysis & Transplantation 39:11, 468-469
CrossRef418
Joana Mesquita, Ana Varela, José Luís Medina. (2010) Dyslipidemia in renal disease: Causes, consequences and treatment. Endocrinología y Nutrición 57:9, 440-448
CrossRef419
A. D. van Zuilen, P. J. Blankestijn, M. van Buren, M. A. G. J. ten Dam, K. A. H. Kaasjager, G. Ligtenberg, Y. W. J. Sijpkens, H. E. Sluiter, P. J. G. van de Ven, G. Vervoort, L.-J. Vleming, M. L. Bots, J. F. M. Wetzels, . (2010) Quality of care in patients with chronic kidney disease is determined by hospital specific factors. Nephrology Dialysis Transplantation 25:11, 3647-3654
CrossRef420
(2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. The Lancet 376:9753, 1670-1681
CrossRef421
C. Sanchez-Perales, E. Vazquez, M. J. Garcia-Cortes, J. Borrego, M. Polaina, C. P. Gutierrez, C. Lozano, A. Liebana. (2010) Ischaemic stroke in incident dialysis patients. Nephrology Dialysis Transplantation 25:10, 3343-3348
CrossRef422
Arjun D. Sinha, Rajiv Agarwal. (2010) Should All Hypertensive Dialysis Patients Receive a Blocker of the Renin-Angiotensin System?. Current Hypertension Reports 12:5, 356-363
CrossRef423
Andrew A. House, Mikko Haapio, Johan Lassus, Rinaldo Bellomo, Claudio Ronco. (2010) Therapeutic Strategies for Heart Failure in Cardiorenal Syndromes. American Journal of Kidney Diseases 56:4, 759-773
CrossRef424
George Bakris, Joseph Vassalotti, Eberhard Ritz, Christoph Wanner, George Stergiou, Mark Molitch, Richard Nesto, George A Kaysen, James R Sowers. (2010) National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. Kidney International 78:8, 726-736
CrossRef425
Karl Winkler, Michael M. Hoffmann. (2010) Response to the letter to the editor. Atherosclerosis 212:2, 697
CrossRef426
A. Poli, A. Corsini. (2010) Reversible and non-reversible cardiovascular risk in patients treated with lipid-lowering therapy: Analysis of SEAS and JUPITER trials. European Journal of Internal Medicine 21:5, 372-373
CrossRef427
Peter P Toth, Alberico Catapano, Joanne E Tomassini, Andrew M Tershakovec. (2010) Update on the efficacy and safety of combination ezetimibe plus statin therapy. Clinical Lipidology 5:5, 655-684
CrossRef428
Juan J. Carrero, Peter Stenvinkel. (2010) Inflammation in End-Stage Renal Disease-What Have We Learned in 10 Years?. Seminars in Dialysis 23:5, 498-509
CrossRef429
Deeptankar DeMazumder, Rani K. Hasan, Roger S. Blumenthal, Erin D. Michos, Steven Jones. (2010) Should Statin Therapy Be Allocated on the Basis of Global Risk or on the Basis of Randomized Trial Evidence?. The American Journal of Cardiology 106:6, 905-909
CrossRef430
Robert E. Cronin, Robert F. Reilly. (2010) Unfractionated Heparin for Hemodialysis: Still the Best Option. Seminars in Dialysis 23:5, 510-515
CrossRef431
B. Coll, A. Betriu, M. Martinez-Alonso, M. Borras, L. Craver, M. L. Amoedo, M. {a. }P. Marco, F. Sarro, M. Junyent, J. M. Valdivielso, E. Fernandez. (2010) Cardiovascular risk factors underestimate atherosclerotic burden in chronic kidney disease: usefulness of non-invasive tests in cardiovascular assessment. Nephrology Dialysis Transplantation 25:9, 3017-3025
CrossRef432
Nosratola D. Vaziri. (2010) Lipotoxicity and Impaired High Density Lipoprotein-Mediated Reverse Cholesterol Transport in Chronic Kidney Disease. Journal of Renal Nutrition 20:5, S35-S43
CrossRef433
T. X. Pedersen, C. J. Binder, G. N. Fredrikson, J. Nilsson, S. Bro, L. B. Nielsen. (2010) The pro-inflammatory effect of uraemia overrules the anti-atherogenic potential of immunization with oxidized LDL in apoE-/- mice. Nephrology Dialysis Transplantation 25:8, 2486-2491
CrossRef434
Lorenzo Arnaboldi, Alberto Corsini. (2010) Do structural differences in statins correlate with clinical efficacy?. Current Opinion in Lipidology 21:4, 298-304
CrossRef435
Allison J. Hahr, Mark E. Molitch. (2010) Diabetes, Cardiovascular Risk and Nephropathy. Cardiology Clinics 28:3, 467-475
CrossRef436
Matthew A. Roberts, David L. Hare. (2010) JUPITER “Moderate CKD” Subgroup Is Not Truly “Moderate” Chronic Kidney Disease. Journal of the American College of Cardiology 56:6, 528
CrossRef437
Joel C Marrs, Joseph J Saseen. (2010) Effects of Lipid-Lowering Therapy on Reduction of Cardiovascular Events in Patients with End-Stage Renal Disease Requiring Hemodialysis. Pharmacotherapy 30:8, 823-829
CrossRef438
John R Guyton. (2010) Combination regimens with statin, niacin, and intestinally active LDL-lowering drugs: alternatives to high-dose statin therapy?. Current Opinion in Lipidology 21:4, 372-377
CrossRef439
Giovanni Tripepi, Francesco Mattace-Raso, Francesco Rapisarda, Benedetta Stancanelli, Lorenzo Malatino, Jacqueline Witteman, Carmine Zoccali, Francesca Mallamaci. (2010) Traditional and nontraditional risk factors as predictors of cerebrovascular events in patients with end stage renal disease. Journal of Hypertension1
CrossRef440
J.L. Górriz Teruel, S. Beltrán Catalán. (2010) Cambios inducidos por la enfermedad renal crónica en los pacientes con diabetes. Avances en Diabetología 26:4, 235-241
CrossRef441
Dena E. Rifkin, Mark J. Sarnak. (2010) Chronic kidney disease: Absence of evidence or evidence of absence? ACS treatment in CKD. Nature Reviews Nephrology 6:8, 449-450
CrossRef442
Raymond T. Krediet, Olga Balafa. (2010) Cardiovascular risk in the peritoneal dialysis patient. Nature Reviews Nephrology 6:8, 451-460
CrossRef443
Ngan N Lam, Amit X Garg. (2010) The Authors Reply:. Kidney International 78:1, 112-112
CrossRef444
Hidenori Koyama, Yoshiki Nishizawa. (2010) AGEs/RAGE in CKD: irreversible metabolic memory road toward CVD?. European Journal of Clinical Investigation 40:7, 623-635
CrossRef445
Sheila L. Stadler, Bharati Bhardwaja, Kari L. Olson, J. David Powers, Diane Lanese. (2010) An assessment of cholesterol goal attainment in patients with chronic kidney disease. Journal of Clinical Lipidology 4:4, 298-304
CrossRef446
D. Kiski, H. Reinecke. (2010) Herz und Niere. Der Internist 51:7, 850-856
CrossRef447
Thiane Gama Axelsson, Gerd Faxén Irving, Jonas Axelsson. (2010) To Eat or Not to Eat: Dietary Fat in Uremia Is the Question. Seminars in Dialysis 23:4, 383-388
CrossRef448
Eberhard Ritz, Christoph Wanner. (2010) Statins: do we definitely know whether they are completely inefficacious in ESRD?. Kidney International 78:1, 111-112
CrossRef449
Petter Quist-Paulsen. (2010) Statins and inflammation: an update. Current Opinion in Cardiology 25:4, 399-405
CrossRef450
Dena E. Rifkin, Wolfgang C. Winkelmayer. (2010) Medication Issues in Older Individuals With CKD. Advances in Chronic Kidney Disease 17:4, 320-328
CrossRef451
Allon N. Friedman. (2010) Omega-3 Fatty Acid Supplementation in Advanced Kidney Disease. Seminars in Dialysis 23:4, 396-400
CrossRef452
P. A. McCullough, M. Haapio, S. Mankad, N. Zamperetti, B. Massie, R. Bellomo, T. Berl, S. D. Anker, I. Anand, N. Aspromonte, S. M. Bagshaw, I. Bobek, D. N. Cruz, L. Daliento, A. Davenport, H. Hillege, A. A. House, N. Katz, A. Maisel, A. Mebazaa, A. Palazzuoli, P. Ponikowski, F. Ronco, A. Shaw, G. Sheinfeld, S. Soni, G. Vescovo, P. Zanco, C. Ronco, T. Berl, . (2010) Prevention of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference. Nephrology Dialysis Transplantation 25:6, 1777-1784
CrossRef453
Haseeb Jafri, Alawi A. Alsheikh-Ali, Richard H. Karas. (2010) Baseline and On-Treatment High-Density Lipoprotein Cholesterol and the Risk of Cancer in Randomized Controlled Trials of Lipid-Altering Therapy. Journal of the American College of Cardiology 55:25, 2846-2854
CrossRef454
Héloïse Cardinal, François Madore. (2010) La pharmacopée de prévention cardiovasculaire est-elle sous-utilisée chez les patients souffrant d’insuffisance rénale chronique après un infarctus du myocarde ?. Néphrologie & Thérapeutique 6:3, 162-170
CrossRef455
F. Moreso, N. Calvo, J. Pascual, F. Anaya, C. Jimenez, D. del Castillo, J. Sanchez-Plumed, D. Seron. (2010) Early statin use is an independent predictor of long-term graft survival. Clinical Kidney Journal 3:suppl 2, ii26-ii31
CrossRef456
Anne-Emilie Declèves, Kumar Sharma. (2010) New pharmacological treatments for improving renal outcomes in diabetes. Nature Reviews Nephrology 6:6, 371-380
CrossRef457
Rajan K. Patel, Alan G.M. Jardine, Patrick B. Mark, Anthony F. Cunningham, Tracey Steedman, Joanna R. Powell, Emily P. McQuarrie, Kathryn K. Stevens, Henry J. Dargie, Alan G. Jardine. (2010) Association of Left Atrial Volume With Mortality Among ESRD Patients With Left Ventricular Hypertrophy Referred for Kidney Transplantation. American Journal of Kidney Diseases 55:6, 1088-1096
CrossRef458
Thomas T Tsai, Brahmahjee K Nallamothu. (2010) Percutaneous coronary intervention in patients with chronic kidney disease: where’s the evidence?. Interventional Cardiology 2:3, 253-256
CrossRef459
Bernd Krüger, Andreas Walberer, Jens Debler, Carsten A. Böger, Stefan Farkas, Stephan W. Reinhold, Aiman Obed, Hans Jürgen Schlitt, Michael Fischereder, Bernhard Banas, Bernhard K. Krämer. (2010) Is inflammation prior to renal transplantation predictive for cardiovascular and renal outcomes?. Atherosclerosis 210:2, 637-642
CrossRef460
David Lewis, Richard Haynes, Martin J. Landray. (2010) LIPIDS IN CHRONIC KIDNEY DISEASE. Journal of Renal Care 36, 27-33
CrossRef461
Emily P. McQuarrie, Bengt C. Fellström, Hallvard Holdaas, Alan G. Jardine. (2010) CARDIOVASCULAR DISEASE IN RENAL TRANSPLANT RECIPIENTS. Journal of Renal Care 36, 136-145
CrossRef462
Mike Seddon, Nick Curzen. (2010) CORONARY REVASCULARISATION IN CHRONIC KIDNEY DISEASE PART 1: STABLE CORONARY ARTERY DISEASE. Journal of Renal Care 36, 106-117
CrossRef463
J.P. Cambou, V. Aboyans, J. Constans, P. Lacroix, C. Dentans, A. Bura. (2010) Characteristics and Outcome of Patients Hospitalised for Lower Extremity Peripheral Artery Disease in France: The COPART Registry. European Journal of Vascular and Endovascular Surgery 39:5, 577-585
CrossRef464
Katrin Uhlig. (2010) There Is No Practical Utility in Routinely Screening Dialysis Patients for Vascular Calcification. Seminars in Dialysis 23:3, 277-279
CrossRef465
Irene M. Van Der Meer, Piero Ruggenenti, Giuseppe Remuzzi. (2010) THE DIABETIC CKD PATIENT-A MAJOR CARDIOVASCULAR CHALLENGE. Journal of Renal Care 36, 34-46
CrossRef466
Nosratola D. Vaziri, Mohamad Navab, Alan M. Fogelman. (2010) HDL metabolism and activity in chronic kidney disease. Nature Reviews Nephrology 6:5, 287-296
CrossRef467
Shin-ichiro Miura, Keijiro Saku. (2010) Effects of statin and lipoprotein metabolism in heart failure. Journal of Cardiology 55:3, 287-290
CrossRef468
Sabin Shurraw, Sumit R. Majumdar, Ravi Thadhani, Natasha Wiebe, Marcello Tonelli. (2010) Glycemic Control and the Risk of Death in 1,484 Patients Receiving Maintenance Hemodialysis. American Journal of Kidney Diseases 55:5, 875-884
CrossRef469
Qiangjun Cai, Ricardo Serrano, Arun Kalyanasundaram, Jamshid Shirani. (2010) A Preoperative Echocardiographic Predictive Model for Assessment of Cardiovascular Outcome after Renal Transplantation. Journal of the American Society of Echocardiography 23:5, 560-566
CrossRef470
Min Jun, Celine Foote, Jicheng Lv, Bruce Neal, Anushka Patel, Stephen J Nicholls, Diederick E Grobbee, Alan Cass, John Chalmers, Vlado Perkovic. (2010) Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. The Lancet 375:9729, 1875-1884
CrossRef471
Robert M. Califf, Yuliya Lokhnygina, Christopher P. Cannon, Michael E. Stepanavage, Carolyn H. McCabe, Thomas A. Musliner, Richard C. Pasternak, Michael A. Blazing, Robert P. Giugliano, Robert A. Harrington, Eugene Braunwald. (2010) An update on the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design. American Heart Journal 159:5, 705-709
CrossRef472
Manish P. Ponda, Irina Barash, Jonathan E. Feig, Edward A. Fisher, Edward Y. Skolnik. (2010) Moderate kidney disease inhibits atherosclerosis regression. Atherosclerosis 210:1, 57-62
CrossRef473
Ranjani N. Moorthi, Sharon M. Moe, Tilman Drüeke, Katrin Uhlig. (2010) All Research Does Not a Guideline Make!. American Journal of Kidney Diseases 55:4, 631-634
CrossRef474
Vivencio Barrios, Carlos Escobar. (2010) Rosuvastatin and Cardiovascular Continuum. Journal of the American College of Cardiology 55:15, 1645-1646
CrossRef475
Patrick B. Mark, Rajan K. Patel, Alan G. Jardine. (2010) Screening for Coronary Artery Disease Before Renal Transplantation—Rational or Rationing?. Transplantation 89:7, 807-808
CrossRef476
John G.F. Cleland, John J.V. McMurray, John Kjekshus. (2010) Reply. Journal of the American College of Cardiology 55:15, 1646
CrossRef477
(2010) Journal Club. Kidney International 77:7, 563-564
CrossRef478
Eugenie Pedagogos. (2010) Coronary artery, cerebrovascular and peripheral vascular disease. Nephrology 15, S19-S23
CrossRef479
José Jayme G. De Lima, Luís Henrique W. Gowdak, Flávio Jota de Paula, Rodolfo L. Arantes, André Luís Veiga de Oliveira, Jose Antonio F. Ramires, Luiz Antonio M. César, Eduardo M. Krieger. (2010) Treatment of Coronary Artery Disease in Hemodialysis Patients Evaluated for Transplant—A Registry Study. Transplantation 89:7, 845-850
CrossRef480
Javier Sanz, Pedro R. Moreno, Valentin Fuster. (2010) The Year in Atherothrombosis. Journal of the American College of Cardiology 55:14, 1487-1498
CrossRef481
W. H. Wilson Tang, Gary S. Francis. (2010) Statin treatment for patients with heart failure. Nature Reviews Cardiology
CrossRef482
Tejas Patel, David M. Charytan. (2010) Cardiovascular Complications in Diabetic Kidney Disease. Seminars in Dialysis 23:2, 169-177
CrossRef483
Pedro L. Neves, Anabela Malho, Ana Cabrita, Ana Pinho, Alexandre Baptista, Elsa Morgado, Marília Faísca, Hermínio Carrasqueira, Ana P. Silva. (2010) Statins and vitamin D: a friendly association in pre-dialysis patients. International Urology and Nephrology 42:1, 173-179
CrossRef484
Francesco Locatelli, Lucia Del Vecchio, Andrea Cavalli. (2010) How Can Prognosis for Diabetic ESRD Be Improved?. Seminars in Dialysis 23:2, 214-219
CrossRef485
Tanveer Ahmad Wani, Abdus Samad, Monika Tandon, Gurpreet S. Saini, P. L. Sharma, K. K. Pillai. (2010) The Effects of Rosuvastatin on the Serum Cortisol, Serum Lipid, and Serum Mevalonic Acid Levels in the Healthy Indian Male Population. AAPS PharmSciTech 11:1, 425-432
CrossRef486
Radica Z. Alicic, Katherine R. Tuttle. (2010) Management of the Diabetic Patient with Advanced Chronic Kidney Disease. Seminars in Dialysis 23:2, 140-147
CrossRef487
Holger Schmid, Helmut Schiffl, Stephan R Lederer. (2010) Pharmacotherapy of end-stage renal disease. Expert Opinion on Pharmacotherapy 11:4, 597-613
CrossRef488
Paul M. Ridker, Jean MacFadyen, Michael Cressman, Robert J. Glynn. (2010) Efficacy of Rosuvastatin Among Men and Women With Moderate Chronic Kidney Disease and Elevated High-Sensitivity C-Reactive Protein. Journal of the American College of Cardiology 55:12, 1266-1273
CrossRef489
C. Rinat, R. Becker-Cohen, A. Nir, S. Feinstein, D. Shemesh, N. Algur, E. Ben Shalom, B. Farber, Y. Frishberg. (2010) A comprehensive study of cardiovascular risk factors, cardiac function and vascular disease in children with chronic renal failure. Nephrology Dialysis Transplantation 25:3, 785-793
CrossRef490
Daniela V Barreto, Fellype C Barreto, Sophie Liabeuf, Mohammed Temmar, Horst-Dieter Lemke, Christophe Tribouilloy, Gabriel Choukroun, Raymond Vanholder, Ziad A Massy. (2010) Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney International 77:6, 550-556
CrossRef491
Jan Galle. (2010) Das kardiorenale Syndrom. Medizinische Klinik 105:3, 142-149
CrossRef492
ASMIR I. SYED, ITSIK BEN-DOR, SARA D. COLLINS, MANUEL A. GONZALEZ, MICHAEL A. GAGLIA, Jr., REBECCA TORGUSON, LOWELL F. SATLER, WILLIAM O. SUDDATH, AUGUSTO D. PICHARD, JOSEPH LINDSAY, RON WAKSMAN. (2010) Sirolimus-Eluting Stents versus Paclitaxel-Eluting Stents in Patients with Chronic Renal Insufficiency. Journal of Interventional Cardiology 23:1, 33-39
CrossRef493
Scott L. Charland, Daniel C. Malone. (2010) Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy. Current Medical Research and Opinion 26:2, 365-375
CrossRef494
Sabin Shurraw, Marcello Tonelli. (2010) AURORA: Is There a Role for Statin Therapy in Dialysis Patients?. American Journal of Kidney Diseases 55:2, 237-240
CrossRef495
(2010) Journal Club. Medizinische Klinik 105:2, 111-117
CrossRef496
C. A. Herzog. (2010) Kidney disease in cardiology. Nephrology Dialysis Transplantation 25:2, 356-360
CrossRef497
Jocelyn Wiggins, Sanjeevkumar Patel. (2010) Management of chronic kidney disease in older adults. Aging Health 6:1, 41-51
CrossRef498
M. de Lorgeril. (2010) Statines et diabète : mauvaise science ou mauvaise médecine ?. Médecine des Maladies Métaboliques 4:1, 79-81
CrossRef499
Abboud , Hanna , Henrich , William L. , . (2010) Stage IV Chronic Kidney Disease. New England Journal of Medicine 362:1, 56-65
Full Text500
M. Farnier. (2010) Dyslipidémies et risque cardiovasculaire : données des études de prévention cardiovasculaire. EMC - Endocrinologie - Nutrition 7:4, 1-13
CrossRef501
Mike J. L. Peters, Michael T. Nurmohamed, George D. Kitas, Naveed Sattar. (2010) Statin treatment of rheumatoid arthritis: Comment on the editorial by Ridker and Solomon. Arthritis & Rheumatism 62:1, 302-303
CrossRef502
Nigel D. Toussaint, Grahame J. Elder, Peter G. Kerr. (2010) A Rational Guide to Reducing Fracture Risk in Dialysis Patients. Seminars in Dialysis 23:1, 43-54
CrossRef503
Csaba P. Kovesdy, Kamyar Kalantar-Zadeh. Inflammation in Chronic Kidney Disease. In: Chronic Kidney Disease, Dialysis, and Transplantation. Elsevier, 2010:183-197.
CrossRef504
H. Pieringer, M. Pichler. (2010) Cardiovascular morbidity and mortality in patients with rheumatoid arthritis: vascular alterations and possible clinical implications. QJM 104:1, 13
CrossRef505
S Ananth Karumanchi, Ravi Thadhani. (2010) Kidney complications: Why don't statins always work?. Nature Medicine 16:1, 38-40
CrossRef506
M. Ketteler, P.H. Biggar. (2010) Kardiorenales Syndrom. Der Nephrologe 5:1, 49-57
CrossRef507
Richard J. Glassock, Roberto Pecoits-Filho, Silvio Barbareto. (2010) Increased Left Ventricular Mass in Chronic Kidney Disease and End-Stage Renal Disease: What Are the Implications?. Dialysis & Transplantation 39:1, 16-19
CrossRef508
, Giovanni FM Strippoli. (2010) Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocol. Trials 11:1, 70
CrossRef509
Tariq Shafi, Josef Coresh. Chronic Kidney Disease. In: Chronic Kidney Disease, Dialysis, and Transplantation. Elsevier, 2010:3-21.
CrossRef510
ASMIR I. SYED, ITSIK BEN-DOR, SARA D. COLLINS, MANUEL A. GONZALEZ, MICHAEL A. GAGLIA, Jr., REBECCA TORGUSON, LOWELL F. SATLER, WILLIAM O. SUDDATH, AUGUSTO D. PICHARD, JOSEPH LINDSAY, RON WAKSMAN. (2010) Sirolimus-Eluting Stents versus Paclitaxel-Eluting Stents in Patients with Chronic Renal Insufficiency. Journal of Interventional Cardiology
CrossRef511
K. Amann, K. Benz. (2010) Statins--beyond lipids in CKD. Nephrology Dialysis Transplantation 26:2, 407
CrossRef512
Karl Winkler, Michael M. Hoffmann, Vera Krane, Winfried März, Christiane Drechsler, Christoph Wanner. (2010) Apolipoprotein E genotype predicts cardiovascular endpoints in dialysis patients with type 2 diabetes mellitus. Atherosclerosis 208:1, 197-202
CrossRef513
Hidenori Yagi, Makoto Kawai, Kimiaki Komukai, Takayuki Ogawa, Kosuke Minai, Tomohisa Nagoshi, Kazuo Ogawa, Hiroshi Sekiyama, Ikuo Taniguchi, Michihiro Yoshimura. (2010) Impact of chronic kidney disease on the severity of initially diagnosed coronary artery disease and the patient prognosis in the Japanese population. Heart and Vessels 26:4, 370
CrossRef514
Stephen L Seliger. (2010) Comorbidity and confounding in end-stage renal disease. Kidney International 77:2, 83-85
CrossRef515
Katherine R. Tuttle. Complications and Management of Chronic Kidney Disease. In: Chronic Kidney Disease, Dialysis, and Transplantation. Elsevier, 2010:145-163.
CrossRef516
Aidar R. Gosmanov. (2010) Rebuttal to Counterpoint. Journal of Clinical Lipidology 4:1, 74
CrossRef517
N.R. Robles, J.F. Macias. (2010) Cardiovascular Risk in Uremic Patients: Darkness after AURORA. Renal Failure 32:2, 269-272
CrossRef518
Sachiko Hattori, Yoshiyuki Hattori. (2010) Efficacy and safety of ezetimibe in patients undergoing hemodialysis. Endocrine Journal 57:11, 1001-1005
CrossRef519
Yoichi Ogushi, Yasuo Haruki, Takeo Shibata, Shotai Kobayashi, JSSRS Group. (2010) Hyperlipidemia effects on clinical indexes of stroke in Japanese patients. Nosotchu 32:3, 242-253
CrossRef520
E. J. Mills, P. WU, G. Chong, I. Ghement, S. Singh, E. A. Akl, O. Eyawo, G. Guyatt, O. Berwanger, M. Briel. (2010) Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170 255 patients from 76 randomized trials. QJM 104:2, 109
CrossRef521
Michel de Lorgeri, Patricia Salen. (2010) Recent cholesterol-lowering drug trials: New data, new questions. Journal of Lipid Nutrition 19:1, 65-92
CrossRef522
Lynda A. Szczech. (2010) Chronic kidney disease: Did 'renalism' skew the results of a negative study?. Nature Reviews Nephrology 6:1, 18-20
CrossRef523
Daniel E. Weiner, Mark J. Sarnak. Cardiovascular Disease in Patients with Chronic Kidney Disease. In: Chronic Kidney Disease, Dialysis, and Transplantation. Elsevier, 2010:128-144.
CrossRef524
Simon R. Knight, Peter J. Morris. (2010) Steroid Avoidance or Withdrawal After Renal Transplantation Increases the Risk of Acute Rejection but Decreases Cardiovascular Risk. A Meta-Analysis. Transplantation 89:1, 1-14
CrossRef525
Dimitrios Kirmizis, Aikaterini Papagianni, Fani Dogrammatzi, Lemonia Skoura, Anna-Maria Belechri, Efstathios Alexopoulos, Georgios Efstratiadis, Dimitrios Memmos. (2010) Effects of simvastatin on markers of inflammation, oxidative stress and endothelial cell apoptosis in patients on chronic hemodialysis. Journal of Atherosclerosis and Thrombosis 17:12, 1256-1265
CrossRef526
Wolfgang C. Winkelmayer. Kidney Disease and Medications. In: Chronic Kidney Disease, Dialysis, and Transplantation. Elsevier, 2010:208-217.
CrossRef527
Nadezda Koleganova, Grzegorz Piecha, Eberhard Ritz. (2010) Vasculotropic effects of calcimimetics. Current Opinion in Nephrology and Hypertension 19:1, 32-36
CrossRef528
Manish M. Sood, Marisa Battistella, Charmaine E. Lok. (2009) Patterns of cardioprotective medication prescription in incident hemodialysis patients. International Urology and Nephrology 41:4, 1021-1027
CrossRef529
Vincent M Brandenburg, Willi Jahnen-Dechent, Markus Ketteler. (2009) Sevelamer and the bone–vascular axis in chronic kidney disease: bone turnover, inflammation, and calcification regulation. Kidney International 76, S26-S33
CrossRef530
Rahul Sakhuja, Ashok J. Shah, Swapnil Hiremath, Ranjan K. Thakur. (2009) End-Stage Renal Disease and Sudden Cardiac Death. Cardiac Electrophysiology Clinics 1:1, 61-77
CrossRef531
Xiong Z. Ruan, Zac Varghese, John F. Moorhead. (2009) An update on the lipid nephrotoxicity hypothesis. Nature Reviews Nephrology 5:12, 713-721
CrossRef532
D. Goldsmith, A. Covic. (2009) Blood pressure control in CKD stage 5D patients--are we more or less certain what to do in 2009?. Nephrology Dialysis Transplantation 24:12, 3597-3601
CrossRef533
Jonathan Himmelfarb. (2009) Uremic Toxicity, Oxidative Stress, and Hemodialysis as Renal Replacement Therapy. Seminars in Dialysis 22:6, 636-643
CrossRef534
(2009) Journal Club. Kidney International 76:9, 923-924
CrossRef535
Devasmita Choudhury, Meryem Tuncel, Moshe Levi. (2009) Disorders of Lipid Metabolism and Chronic Kidney Disease in the Elderly. Seminars in Nephrology 29:6, 610-620
CrossRef536
D E Weiner. (2009) Public Health Consequences of Chronic Kidney Disease. Clinical Pharmacology & Therapeutics 86:5, 566-569
CrossRef537
A.-S. Bargnoux, A.-M. Dupuy, V. Garrigue, I. Jaussent, G. Gahide, S. Badiou, I. Szwarc, S. Deleuze, H. Vernhet, J.-P. Cristol, G. Mourad. (2009) Evolution of Coronary Artery Calcifications Following Kidney Transplantation: Relationship with Osteoprotegerin Levels. American Journal of Transplantation 9:11, 2571-2579
CrossRef538
Eric P Cohen, Jean-Marie Krzesinski. (2009) C-reactive protein and dialysis access. Kidney International 76:10, 1025-1026
CrossRef539
Lori B. Daniels, Elizabeth Barrett-Connor. (2009) Can Natriuretic Peptides Help Identify Heart Failure Patients for Whom Statins Are Beneficial?. Journal of the American College of Cardiology 54:20, 1860-1861
CrossRef540
Helen M. Colhoun, D. John Betteridge, Paul N. Durrington, Graham A. Hitman, H. Andrew W. Neil, Shona J. Livingstone, Valentine Charlton-Menys, David A. DeMicco, John H. Fuller. (2009) Effects of Atorvastatin on Kidney Outcomes and Cardiovascular Disease in Patients With Diabetes: An Analysis From the Collaborative Atorvastatin Diabetes Study (CARDS). American Journal of Kidney Diseases 54:5, 810-819
CrossRef541
Vivencio Barrios, Carlos Escobar. (2009) Rosuvastatin along the cardiovascular continuum: from JUPITER to AURORA. Expert Review of Cardiovascular Therapy 7:11, 1317-1327
CrossRef542
Jacques Genest, Ruth McPherson, Jiri Frohlich, Todd Anderson, Norm Campbell, André Carpentier, Patrick Couture, Robert Dufour, George Fodor, Gordon A. Francis, Steven Grover, Milan Gupta, Robert A. Hegele, David C. Lau, Lawrence Leiter, Gary F. Lewis, Eva Lonn, G.B. John Mancini, Dominic Ng, Glen J. Pearson, Allan Sniderman, James A. Stone, Ehud Ur. (2009) 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations. Canadian Journal of Cardiology 25:10, 567-579
CrossRef543
Sankar D. Navaneethan, Suetonia C. Palmer, Jonathan C. Craig, Grahame J. Elder, Giovanni F.M. Strippoli. (2009) Benefits and Harms of Phosphate Binders in CKD: A Systematic Review of Randomized Controlled Trials. American Journal of Kidney Diseases 54:4, 619-637
CrossRef544
Charles van Heyningen. (2009) Lipid metabolism and causal pathways for cardiovascular disease in chronic kidney disease. Current Opinion in Lipidology 20:5, 440-441
CrossRef545
Tamara Isakova, Orlando M Gutiérrez, Myles Wolf. (2009) A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease. Kidney International 76:7, 705-716
CrossRef546
Raphael See, Robert N. Piana. (2009) Achieving optimum lipid-lowering goals in patients with vascular disease. Current Cardiovascular Risk Reports 3:5, 323-330
CrossRef547
Terje R. Pedersen. (2009) Lipid-lowering drugs and risk for cancer. Current Atherosclerosis Reports 11:5, 350-357
CrossRef548
Richard A. Sherman. (2009) Briefly Noted. Seminars in Dialysis 22:5, 595-596
CrossRef549
Sarina van der Zee, Usman Baber, Sammy Elmariah, Jonathan Winston, Valentin Fuster. (2009) Cardiovascular risk factors in patients with chronic kidney disease. Nature Reviews Cardiology 6:9, 580-589
CrossRef550
Philip R. Liebson. (2009) ACTIVE A and AURORA. Preventive Cardiology 12:4, 205-208
CrossRef551
Carmine Zoccali. (2009) Dialysis: The sweetness of glitazones: randomized trials needed. Nature Reviews Nephrology 5:9, 497-498
CrossRef552
(2009) Chapter 3.1: Diagnosis of CKD–MBD: biochemical abnormalities. Kidney International 76, S22-S49
CrossRef553
Anthony J. Joseph, Eli A. Friedman. (2009) Diabetic Nephropathy in the Elderly. Clinics in Geriatric Medicine 25:3, 373-389
CrossRef554
Per-Ola Attman, Ola Samuelsson. (2009) Dyslipidemia of kidney disease. Current Opinion in Lipidology 20:4, 293-299
CrossRef555
J. Floege. (2009) Reply. Nephrology Dialysis Transplantation 24:8, 2610-2611
CrossRef556
Sarbjit Vanita Jassal. (2009) Clinical Presentation of Renal Failure in the Aged: Chronic Renal Failure. Clinics in Geriatric Medicine 25:3, 359-372
CrossRef557
Michal Chmielewski, Boleslaw Rutkowski, Bengt Lindholm. (2009) Mechanisms and clinical implications of lipid disorders in chronic kidney disease. Clinical Lipidology 4:4, 449-456
CrossRef558
(2009) Rosuvastatin in Patients Undergoing Hemodialysis. New England Journal of Medicine 361:1, 93-95
Free Full Text559
Joachim H. Ix, Glenn M. Chertow. (2009) Dialysis: Phosphorus binders and survival: need for randomized trials. Nature Reviews Nephrology 5:7, 368-370
CrossRef560
D. Benson Walker, Thanh Jennifer Walker, Terry A. Jacobson. (2009) Chronic kidney disease and statins: Improving cardiovascular outcomes. Current Atherosclerosis Reports 11:4, 301-308
CrossRef561
Chloë Harman. (2009) Dialysis: AURORA confirms lack of statin benefit in dialysis patients. Nature Reviews Nephrology 5:7, 363-363
CrossRef562
D. C. Wheeler. (2009) The Jupiter trial--new territory for statins?. Nephrology Dialysis Transplantation 24:7, 2036-2037
CrossRef563
Raphaelle L. Dumaine, Gilles Montalescot, Ph. Gabriel Steg, E. Magnus Ohman, Kim Eagle, Deepak L. Bhatt. (2009) Renal function, atherothrombosis extent, and outcomes in high-risk patients. American Heart Journal 158:1, 141-148.e1
CrossRef564
Javier Segovia, Javier Bermejo, Fernando Alfonso. (2009) Summary of the Clinical Studies Reported in the 58th Scientific Session of the American College of Cardiology (Orlando, USA, March 28-31, 2009). Revista Española de Cardiología (English Edition) 62:6, 660-669
CrossRef565
Vinod K. Bansal. (2009) Dyslipidemia in ESRD: Too Late to Treat?. Nephrology Times 2:6, 2
CrossRef566
Javier Segovia, Javier Bermejo, Fernando Alfonso. (2009) Resumen de los ensayos clínicos presentados en la 58.ª Sesión Científica Anual del American College of Cardiology (Orlando, Estados Unidos, 28-31 de marzo de 2009). Revista Española de Cardiología 62:6, 660-669
CrossRef567
(2009) Journal Club. Kidney International 75:12, 1249-1250
CrossRef568
Jacyntha A. Sterling. (2009) Hospital Pharmacy Pulse - Recent Publications on Medications and Pharmacy. Hospital Pharmacy 44:6, 526-532
CrossRef569
S. Methven, M. S. MacGregor. (2009) Clinical management of chronic kidney disease. Clinical Medicine 9:3, 269-272
CrossRef570
Lars S. Maier, Magnus Baumhäkel, Michael Böhm. (2009) Hotline sessions presented at the American College of Cardiology Congress 2009. Clinical Research in Cardiology 98:6, 345-352
CrossRef571
John G.F. Cleland, Alison P. Coletta, Andrew L. Clark, Damien Cullington. (2009) Clinical trials update from the American College of Cardiology 2009: ADMIRE-HF, PRIMA, STICH, REVERSE, IRIS, partial ventricular support, FIX-HF-5, vagal stimulation, REVIVAL-3, pre-RELAX-AHF, ACTIVE-A, HF-ACTION, JUPITER, AURORA, and OMEGA. European Journal of Heart Failure 11:6, 622-630
CrossRef572
Gianna Fabbri, Aldo Pietro Maggioni. (2009) Cardiovascular risk reduction: What do recent trials with rosuvastatin tell us?. Advances in Therapy 26:5, 469-487
CrossRef573
Strippoli , Giovanni F.M. , Craig , Jonathan C. , . (2009) Sunset for Statins after AURORA?. New England Journal of Medicine 360:14, 1455-1457
Full Text574
Alistair S. Hall, Beryl M. Jackson, Amanda J. Farrin, Maria Efthymiou, Julian H. Barth, Joanne Copeland, Kristian M. Bailey, Simon P. R. Romaine, Anthony J. Balmforth, Terry McCormack, Andrew Whitehead, Marcus D. Flather, Jane Nixon. (2009) A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events – Reduction of Cholesterol to Key European Targets Trial. European Journal of Cardiovascular Prevention & Rehabilitation 16:6, 712
CrossRef575
David Goldsmith, Adrian C. Covic. (2009) Jupiter or Aurora? Micro-inflammation and dyslipidaemia: twin targets for statin therapy in CKD. International Urology and Nephrology 42:1, 133
CrossRef576
Philipp Eller, Kathrin Eller, Anna M Wolf, Sebastian J Reinstadler, Andrea Tagwerker, Josef R Patsch, Gert Mayer, Alexander R Rosenkranz. (2009) Atorvastatin attenuates murine anti-glomerular basement membrane glomerulonephritis. Kidney International 77:5, 428
CrossRef
- Letters
